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Bradykinin is a nonapetide released into plasma during the contact phase of blood
coagulation. It has a wide variety of physiological effects including vasodilatation,
tissue-type plasminogen activator (t-PA) release, inflammatory mediator, ischaemic
preconditioning and vasculogenesis. It is inactivated in plasma by angiotensin-
converting enzyme (ACE). Inhibition of this enzyme has been shown to be beneficial
in a variety of cardiovascular disorders including heart failure and hypertension, and
it is clear that this benefit is not due entirely to reduction in the bioavailability of
angiotensin II. We hypothesised that
• bradykinin is a vasodilator and stimulates endothelial t-PA release via a
specific receptor and that this effect is augmented by ACE inhibition.
• in patients with heart failure, bradykinin contributes to peripheral and
systemic vascular tone during treatment with ACE inhibition.
Forearm blood flow was measured using bilateral forearm plethysmography during
intrabrachial drug infusion. Bilateral venous cannulae were inserted to perform blood
sampling for estimation of plasma t-PA and plasminogen activator inhibitor 1 (PAI-
1) concentrations. Cardiac output was measured with pulmonary artery
catheterisation. The novel peptide bradykinin receptor antagonist, B9340, was used
to oppose the effects of bradykinin.
Studies were performed in healthy volunteers
• to demonstrate the pharmacodynamics of B9340 and to demonstrate the
selectivity of B9340 in opposing bradykinin-induced t-PA release.
• to demonstrate the safety and tolerability of systemic intravenous B9340
administration.
Studies were performed in patients with heart failure
• to demonstrate the effect ofACE inhibition on endothelial t-PA release.
• to demonstrate the effect of bradykinin antagonism on peripheral and




• Bradykinin and substance P caused dose-dependent vasodilatation in the
infused forearm (p<0.001). B9340 caused a dose-dependent inhibition of
bradykinin-induced forearm vasodilatation and t-PA release (p<0.001)
without affecting substance P-induced vasodilatation or t-PA release (p=NS).
B9340 caused a reversible inhibition of bradykinin-induced vasodilatation
(p<0.001) with a rapid onset and offset of action. Intravenous systemic
B9340 administration inhibited the local bradykinin-induced forearm
vasodilatation in a dose-dependent manner.
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In patients with heart failure
• bradykinin and substance P caused dose-dependent vasodilatation and release
of t-PA from the infused forearm (p<0.05). Long-term ACE inhibitor therapy
caused an increase in forearm vasodilatation (p<0.05) and t-PA release
(p<0.001) during bradykinin, but not substance P, infusion.
• incremental doses of B9340 caused a dose-dependent reduction in forearm
blood flow (p<0.01). After withdrawal of ACE inhibitor therapy, B9340
produced no significant change in forearm blood flow.
• systemic intravenous B9340 administration resulted in greater mean arterial
pressure, systemic vascular resistance, pulmonary arterial wedge pressure,
and mean pulmonary arterial pressure during ACE inhibitor therapy
compared with losartan therapy (p<0.005, p<0.07, p<0.0001, and p<0.05
respectively) or placebo infusion (p<0.005 for all).
We have shown that bradykinin is a potent vasodilator that stimulates endogenous
t-PA release and that these effects are receptor specific and can be blocked by a
bradykinin receptor antagonist. We have also shown that bradykinin does not
contribute to peripheral or systemic vascular tone in health but does contribute to
peripheral and systemic vascular tone in patients with heart failure treated with
chronic ACE inhibition. We believe this suggests that many of the beneficial actions
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1.1 HISTORY OF KALLIKREIN AND BRADYKININ
In 1925, in the course of research on the connection between cardiac and renal
function, it was discovered that intravenous injection of dog urine into another dog
decreased the blood pressure, as measured in the carotid artery with a Frank-Petter
spring manometer. This hypotensive response could be reproduced using human
urine and convinced the investigator, EK Frey, that he had discovered a previously
unknown substance [Frey 1926]. As a surgeon, Frey was untrained in the field and
enlisted the help of a chemist Heinrich Kraut to prepare a stable preparation [Kraut et
al 1930]. This was achieved and the substance was known as 'F-stoff after Frey,
which later became kallikrein as it was found to be abundant in the pancreas. Kraut
also found that the substance had an inactive precursor molecule later termed
prekallikrein. It was later discovered that a plasma molecule of high molecular
weight (HMW), when mixed with kallikrein produced an extremely potent
vasodilator that caused profound hypotension in dogs. This was later termed
kininogen.
In 1949 Rocha E Silva and co-workers were investigating the pharmacological
effects of the venom of the snake Borthops jararaca (Figure 1.1) and discovered that
incubation of the venom with the globulin fraction of plasma resulted in the
formation of a potent vasodilator and smooth muscle stimulator [Rocha E Silva et al
1949], The guinea-pig ileum they were using reacted slowly to the substance
compared with histamine or acetylcholine and was thus named bradykinin. Its effect
was also shown not to be inhibited by antihistamines or atropine proving it to be a
new substance. The subsequent discovery of its structure and synthesis as a
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nonapeptide took a further 12 years limited by the peptide chemistry of the day, but
in 1960 Fox et al showed its effects as a potent vasodilator in man by delivering the
drug via an intra-arterial infusion.
Figure 1.1 Borthops jararaca
1.2 BRADYKININ
1.2.1 STRUCTURE AND FUNCTION
The nonapeptide bradykinin (BK, ArgI-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9) is
one of several endogenous oligopeptides called kinins. They are thought to act as
local (paracrine) hormones, acting near the site at which they are generated.
Bradykinin and the related decapeptide kallidin (Lys°-BK) are the major and the
most important physiologically active components of the mammalian kinin family
formed by the kallikrein-kinin system [Bhoola et al 1992; Blais et al 2000]. On the
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basis of their function and regulation, two independent kallikrein-kinin systems can
be distinguished in humans.
The actions of kinins are mediated by two G-protein-coupled, heptahelical receptor
subtypes Bi and B2, distinguishable on the basis of tissue distribution and their
pharmacological and molecular characteristics [Hess et al 1992; Menke et al 1994;
Minshall et al 1995; Hall 1997]. The bradykinin B2 receptors have high affinity for
bradykinin and kallidin but low affinity for des-Arg9-bradykinin and are
constitutively expressed, ready to respond to newly formed kinins [Regoli and
Barabe 1980], In contrast, bradykinin Bj receptors, exhibit high affinity for des-Arg9-
bradykinin and des-Arg9-kallidin but have a low affinity for bradykinin [Regoli et al
1998], Bi receptors are inducible, only being expressed in response to inflammation
and tissue injury and are formed de novo in various cells including vascular
endothelium [Raidoo et al 1997] by stimuli which activate the cytokinin system,
particularly interleukin 1(3 [Marceau 1995]. When activated by agonists B2 receptors
undergo desensitisation and internalisation. This contributes to the rapid reversibility
of the biological effects in vivo [Austin et al 1997], whereas Bi receptors are not
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Table 1.1 Human Bradykinin Receptor Nomenclature
The majority of the prominent physiological actions of bradykinin seem to be
mediated by the stimulation of the bradykinin B2 receptor [Hall 1997], and include
activation of sensory nerve terminals, induction of the release of pro-inflammatory
and hyperalgesic mediators such as neuropeptides, leukotrienes and cytokines,
increased vascular permeability and induction of vasodilatation [Calixto et al 2000],
These pharmacological effects are the underlying cause of the strong pro¬
inflammatory and nociceptive properties of bradykinin, and it is believed that
excessively increased local bradykinin concentrations contribute significantly to
diseases like septic shock, pancreatitis, oedema, asthma, rhinitis, colitis, arthritis and
pain [Hall 1997; Heitsch 1999; Bock and Longmore 2000; Heitsch 2000; Heitsch
2002], In contrast to these long known 'classical' pro-inflammatory properties of
kinins, they have also been identified to significantly contribute to powerful
organoprotective including cardioprotective mechanisms. It has been shown that
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bradykinin via B2 receptors causes the release of vasoactive molecules such as nitric
oxide [Cockroft et al 1994a; O'Kane et al 1994], prostaglandins (PGI2 and PGE2),
endothelium-derived hyperpolarising factor [Nakashima et al 1993; Miura et al
1999] and tissue-type plasminogen activator (t-PA) [Labinjoh et al 2001]. It also
triggers ischaemic preconditioning [Lessar et al 1999] and the translocation of the
glucose transporter GLUT4 [Rett et al 1996].
1.2.2 Synthesis and Release
The plasma kinin forming system consists of two essential plasma proteins,
prekallikrein and HMW kininogen, that interact once bound to an endothelial cell
surface receptor complex that contains cytokeratin 1, urokinase plasminogen
activator (u-PA) receptor and gC 1 qR. Previously it was thought that when factor XII
is activated to Xlla, it converted plasma prekallikrein to kallikrein and kallikrein
digested HMW kininogen to liberate the nonapeptide bradykinin. However recent
work shows the interaction of HMW kininogen with its endothelial cell surface
receptor is key to the regulated activation of prekallikrein, which circulates in plasma
complexed to HMW kininogen. Work with cultured endothelial cells suggests HMW
kininogen bound prekallikrein is rapidly converted to kallikrein by the enzyme
prolylcarboxypeptidase in a process that is independent of factor XII [Motta et al
1998; Rojkjaer et al 1998]. On cultured endothelial cells and cell matrices, factor XII
activation occurs subsequent to prekallikrein activation (Rojkjaer et al 1998; Motta et
al 2001). Activation of prekallikrein, unlike that of factor XI, can therefore proceed
in the absence of factor Xlla [Shariat-Madar et al 2001] (Figure 1.2).
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Figure 1.2 Assembly and activation of the plasma kallikrein-kininogen system on endothelial
cells. Plasma prekallikrein (PK) circulates in complex with high molecular weight kininogen
(HK). The HK'PK complex binds to a multiprotein receptor complex that consists of
cytokeratin 1 (CK1), urokinase plasminogen activator receptor (uPAR) and gClqR. The
proteins of the HK-PK receptor complex co-localise on endothelial cell membranes. When
HK*PK binds to endothelial cells, PK is rapidly converted to kallikrein (K) by the enzyme
prolylcarboxypeptidase (PRCP), which is constitutively active on endothelial cell membranes.
The resulting kallikrein autodigests its receptor, HK, to liberate bradykinin (BK), which can
liberate tissue plasminogen activator (tPA) from endothelial cells. Kallikrein also activates
factor XII (FXII), which binds to the same multiprotein receptor complex as HK in its absence.
Factor XII is synthesised in the liver and circulates as a single-chain zymogen with
no detectable enzymatic activity [Silverberg and Diehl 1987], It is a large protein
with 596 amino acids and contains domains homologous to fibronectin, plasminogen
and plasminogen activator [Cool et al 1985; Castellino and Beals 1987],
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In contrast to factor XII, prekallikrein does not circulate as a separate protein but is
bound to HMW kininogen in a 1:1 bimolecular complex [Bock et al 1985]. It is this
complex that binds to its endothelial receptor surfaces initiating 'contact activation'
primarily through HMW kininogen. Some of the complex dissociates during contact
binding allowing bradykinin formation to occur both locally and at sites distant from
the initiating reaction [Cochrane and Revak 1980]. High molecular weight kininogen
acts as a coagulation cofactor that can bind factor XI and prekallikrein, and factor
XII may be activated when bound to the same receptor as the HMW kininogen
receptor.
Tissue Pathway
Bradykinin may also be generated via a tissue pathway where a prokallikrein is
converted to tissue kallikrein by as yet uncharacterised enzymes and tissue kallikrein
is secreted locally to digest low molecular weight (LMW) kininogen to generate
lysyl-bradykinin (kallidin), and a plasma aminopeptidase converts kallidin to
bradykinin [Guimaraes et al 1973]. Tissue prekallikrein can be converted to tissue
kallikrein in plasma by both plasmin and plasma kallikrein [Takada et al 1985;
Takahashi et al 1986]. Tissue kallikrein is immunologically and structurally
unrelated to plasma kallikrein and is secreted by various organs or cells such as
salivary glands, kidney, pancreas, prostate, pituitary gland and neutrophils [Ole-
MoiYoi et al 1979; Powers and Nasjletti 1982; Figueroa et al 1989]. Its primary
substrate is LMW kininogen but can cleave HMW kininogen to release kallidin,
which is functionally similar to bradykinin but of lower potency.
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1.2.3 Clearance
Regulation of contact activation occurs via plasma protease inhibitors mainly CI
inhibitor, which is a major inhibitor of factor Xlla, factor XIa and kallikrein but is
not active against other coagulation enzymes [de Agostini et al 1984]. Kallikrein is
also inhibited by a2-macroglobulin [McConnell 1972]. In plasma, bradykinin is first
digested by carboxypeptidase N, which removes the C-terminal arginine to leave
des-Arg9-bradykinin [Sheikh and Kaplan 1989] and then by angiotensin-converting
enzyme (ACE) (kininase II) via its tripeptidase activity (its dipeptidase activity
converts angiotensin I to angiotensin II) [Sheikh and Kaplan 1986] to a quintapeptide
and a tripeptide that are both thought to be inactive. As the pulmonary circulation
contains a large amount of ACE 90-95% of bradykinin is inactivated as it passes
through the lungs [Bonner et al 1990],
1.2.4 Fletcher Trait
Bradykinin's intimate relationship with plasminogen activator can be seen in patients
with Fletcher trait who are deficient in prekallikrein and therefore cannot form
bradykinin via the plasma pathway. This rare disorder is associated with an increase
in myocardial infarction and cerebrovascular accident [Currimbhoy et al 1976;
Harris et al 1989; Hess et al 1991; Kabasawa et al 1991].
1.3 THE ENDOGENOUS FIBRINOLYTIC SYSTEM
Activation of the fibrinolytic system results in the conversion of the inactive
proenzyme, plasminogen to plasmin, the active enzyme. Plasmin degrades fibrin into
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soluble fibrin degradation products thus maintaining the patency of blood vessels. In
addition to specific degradation of fibrin, plasmin is probably also involved in the
cleavage of a variety of proteins on cell surfaces and in the extracellular matrix. All
the enzymes of the fibrinolytic system are serine proteases (their catalytic site
contains the amino acids serine, aspartate, histidine), while the inhibitors of
fibrinolysis are members of the serine protease inhibitors ('serpins') superfamily
[Lijnen and Collen 1995].
1.3.1 Plasminogen
Plasminogen is a 92 kD single-chain glycoprotein, which on activation is converted
to plasmin, a two-chain protein with proteolytic activity. The amino-terminal A-
chain has five kringle domains which mediate the binding of plasminogen to fibrin
(where it is subsequently activated) and the interaction with a2-antiplasmin. The B-
chain contains the proteolytic active site. The main physiologic activators of
plasminogen are t-PA and u-PA. The main synthesis site for u-PA is the kidney.
u-PA is released as a 54 kD single-chain molecule (scu-PA), which has little catalytic
activity and which is cleaved to produce the two-chain molecule (tcu-PA) with a
100-fold increased plasminogen activating capacity [Lijnen et al 1990]. Urokinase
plasminogen activator mediated activation seems to be mainly involved in
pericellular proteolysis whereas plasminogen activation via t-PA is mainly involved
in the dissolution of fibrin in the blood vessels.
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1.3.2 Tissue Plasminogen Activator
Tissue plasminogen activator is synthesised by and released from endothelial cells
into the circulating blood as a single-chain molecule with a molecular mass of 68 kD
[van Hinsbergh 1998]. The activation of plasminogen by t-PA occurs on the fibrin
surface and on the endothelial cell surface. This process allows for efficient and
localised plasminogen activation, since the catalytic activity of surface-bound t-PA is
much higher than in solution [Hoylaerts et al 1982; Plow et al 1991],
The inhibitors of the fibrinolytic systems are a2-antiplasmin, plasminogen activator
inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2). a2-antiplasmin is
a 70 kD single-chain glycoprotein which reacts with plasmin by formation of a 1:1-
molar reversible complex, followed by covalent binding which results in an
irreversible complex. The surface-bound plasmin molecules are protected from the
action of a2-antiplasmin and are inactivated 100-1000 times slower than free plasmin
molecules.
In the absence of fibrin, t-PA has very weak activity as a plasminogen activator.
However, once bound to fibrin, the catalytic activity of t-PA rises a 1000-fold due to
conformational changes resulting from the binding of the finger and second kringle
domains [van Zonneveld et al 1986], and the formation of a ternary complex
between plasminogen, fibrin and t-PA [Ranby 1982],
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Release of tPA occurs in response to ischaemia in the vasculature and fibrin
formation along with direct stimulation by mediators such as bradykinin and
substance-P.
Genetic factors can influence the ability of the endothelium to release tPA in
response to direct stimulation. Patients with the ACE DD genotype have been shown
to have impaired tPA release in response to bradykinin stimulation in the coronary
microvasculature, [Ohira et al 2004] and black Americans have impaired vascular
vasomotor responses to bradykinin compared to white Americans although their tPA
release is similar suggesting different receptor sensitivity to bradykinin between
these two groups. [Rosenbaum et al. 2002]
Disease states can also influence endothelial tPA release. Patients with chronic renal
disease have impaired tPA release in response to DDAVP stimulation despite
preserved vasomotor function. [Hrafnkelsdottir et al 2004] and an increase in tPA
expression was seen in cultured endothelial cells incubated with simvastatin
suggesting that cholesterol lowering with statins may improve tPA release. [Bourcier
and Libby 2000]
1.3.3 Plasminogen activator inhibitor
Plasminogen activator inhibitor 1 is a 52 kD single-chain glycoprotein which is
synthesised in a variety of cells such as endothelial cells, smooth muscle cells,
platelets and hepatocytes. It is stabilised in plasma by binding to vitronectin
[Declerck et al 1988b] which preserves its active conformation and protects it against
oxidation [Lindahl et al 1988]. The plasminogen activator inhibitor 1 concentration
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in plasma exhibits a diurnal variation with a peak in the morning and a trough in the
evening. This variation is opposed to the circadian variation of the t-PA plasma
levels.
Plasminogen activator inhibitor 1 is a rapid inhibitor of t-PA and of tcu-PA but does
not inhibit scu-PA. The reaction pattern is similar to that of plasmin inhibition by a2-
antiplasmin and t-PA bound to fibrin is protected from rapid inhibition by PAI-1 just
as surface-bound plasmin is protected from inhibition by a2-antiplasmin.
Plasminogen activator inhibitor 2 is produced in the placenta and in leukocytes, and
is released into the blood stream during pregnancy. It primarily inhibits tcu-PA and
its physiological role remains incompletely understood [Kruithof et al 1995],
However, recent reports suggest that PAI-2 may play a significant role in cell
proliferation and differentiation [Yu et al 2002], and in the cellular defence
mechanisms against viral infections [Shafren et al 1999]. Plasminogen activator
inhibitor 2 also modulates the expression of adhesion molecules and may inhibit cell
motility and metastasis [Mueller et al 1995].
The clearance of t-PA predominantly occurs through the removal of both active t-PA
and t-PA/PAI-1 complexes from the circulation by the liver [Chandler et al 1997],
This clearance process is rapid, with plasma half-lives for active t-PA and t-PA/PAI-
1 complexes of 2.4 and 5.0 minutes respectively. In the presence of high PAI-1
activity, more t-PA is complexed and the total clearance is slowed due to the longer
half-life of the t-PA/PAI-1 complex. The pharmacodynamics of t-PA clearance
suggest a two compartment model [Chandler et al 1997] and it is likely that
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endothelial cell t-PA receptors contribute significantly to this effect [Cesarman et al
1994],
1.4 ENDOTHELIUM, FUNCTION AND DYSFUNCTION
In 1980, Furchgott and Zawadzki reported that the endothelial cells play an
obligatory role in the relaxations elicited by acetylcholine in isolated arteries of the
rabbit. This pivotal observation has since been extended to a wide variety of arteries
from different species, including humans [Furchgott and Vanhoutte 1989; Liischer
and Vanhoutte 1990], Furchgott, [Furchgott 1988] and Ignarro and colleagues
[Ignarro et al 1987; Ignarro et al 1988] proposed that the endothelial mediator
involved in endothelium-dependent relaxation was nitric oxide which stimulates
soluble guanylate cyclase in vascular smooth muscle cells leading to increased levels
of cyclic guanosine monophosphate (cyclic GMP), and thus relaxation. Moncada and
co-workers [Palmer et al 1987, Palmer et al 1988, Palmer and Moncada 1989]
demonstrated that indeed nitric oxide was the major endothelium-derived relaxing
factor. However, nitric oxide is not the sole mediator of endothelium-dependent
relaxations. In certain blood vessels, prostacyclin, by activating the production of
cyclic adenosine monophosphate (cyclic AMP), can contribute, as can another, as yet
undescribed, endothelium-derived hyperpolarising factor. Since these seminal works
it has been widely recognised that the vascular endothelium acts as a regulator of
vascular function by synthesising and releasing a vast array of mediators that affect
not only vasomotion, but cellular proliferation, haemostasis and inflammation in
response to a variety of stimuli.
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1.4.1 Regulation of vascular tone
The endothelium plays a central role in the regulation of vascular tone by balancing
synthesis and release of the vasodilators nitric oxide, prostacyclin and endothelium-
derived hyperpolarising factor with synthesis and release of vasoconstrictors such as
endothelin. This balance of vasoactive mediators is altered in response to various
stimuli such as bradykinin, acetylcholine and angiotensin II. Both nitric oxide and
endothelin are continuously released by the endothelium to regulate basal vascular
tone [Vallance et al 1989; Haynes and Webb 1994], and their release is affected by
both endocrine and paracrine sources of vasoactive mediators. Dysfunction of the
endothelium results in impaired regulation of vascular tone, endogenous fibrinolysis
and inflammation leading to hypertension and atherosclerosis [Ross 1999].
1.4.2 Regulation of Fibrinolysis and Haemostasis
The regulation of fibrinolysis has been discussed previously in this chapter. The
endothelium provides receptors for several substances involved in endogenous
fibrinolysis. In addition, it synthesises von Willebrand factor, which is a cofactor that
stabilises factor VIII:C and facilitates platelet adhesion to the subendothelial matrix.
1.4.3 Endothelial Dysfunction and Atherosclerosis
Dysfunction of the endothelium in the forearm vascular bed has been shown to be
present in cardiovascular diseases such as hypertension [Linder et al 1990; Panza et
al 1990] and diabetes [Makimatilla et al 1999], as well as patients with risk factors
for atheromatous vascular diseases such as hypercholesterolaemia [Creager et al
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1990; Chowienczyk et al 1992], and smoking [Heitzer et al 1996 Newby et al 1999].
It has been proposed that endothelial dysfunction occurs as a generalised
phenomenon in response to injury of the vasculature and the subsequent complex
inflammatory response to injury leads to inflammatory cell adhesion to the
endothelium with subsequent migration into the vessel wall [Ross 1999].
Strong evidence of a role for endothelial dysfunction as a marker of atherosclerotic
risk stems from several studies investigating the association between the presence of
endothelial dysfunction in both the coronary and systemic circulations and prognosis.
A recent multivariate analysis of current studies describing the association between
coronary or peripheral endothelial dysfunction and cardiovascular events
demonstrated that endothelial dysfunction is strongly and independently associated
with cardiovascular events. This analysis included nearly 2,500 patients, with
duration of follow-up between 1 and 92 months. The nature of the cardiovascular
events varied among the studies but overall represented major cardiovascular events
such as cardiac death, myocardial infarction, and need for revascularisation. Of note
in this analysis was the similar power of coronary and peripheral endothelial
dysfunction to predict cardiovascular events, and that cardiovascular events may
occur remotely from the site in which endothelial dysfunction was detected,
underscoring the systemic nature of endothelial dysfunction [Lerman and Zeiher
2005],
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1.5 RELATIONSHIP BETWEEN THE RENIN-ANGIOTENSIN AND KININ
SYSTEMS
The renin-angiotensin-aldosterone system plays a pivotal role in controlling vascular
tone and blood pressure but it also has an intimate relationship with the kininogen-
kinin system. As can be seen from Figure 1.3 the main link between the two systems
is ACE. This enzyme converts angiotensin I to angiotensin II activating one system










Figure 1.3 Interaction of the plasma kallikrein/kinin system (KKS) with the renin-angiotensin
system (RAS). HK, high molecular weight kininogen; PK, prekallikrein; PRCP,
prolylcarboxypeptidase; HKa, plasma kallikrein-cleaved, high molecular weight kininogen free
of bradykinin; ACE, ANG I converting enzyme; tPA, tissue plasminogen activator; PAI-1,
plasminogen activator inhibitor 1.
Recently, a homologue ofACE, angiotensin-converting enzyme 2 (ACE 2), has been
recognised [Bernstein 2002; Crackower et al 2002], Angiotensin-converting
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enzyme 2 has different substrate specificity than ACE. Angiotensin-converting
enzyme 2 is a carboxypeptidase mainly located in the heart, kidney, and testis. It
degrades angiotensin I by removing the COOH-terminal lysine, making the peptide
angiotensin (1-9), which has been reported to enhance arachidonic acid release by
bradykinin and resensitise the EE receptor [Marcic et al 1999; Bernstein 2002],
Alternatively, ACE degrades angiotensin I by proteolysing it at the penultimate
phenylalanine to produce angiotensin II (angiotensin 1-8). Angiotensin-converting
enzyme 2 is kinetically 100-fold greater than prolylcarboxypeptidase at degrading
angiotensin II to angiotensin (1-7) [Odya et al 1978; Vickers et al 2002], Thus, in
those tissues where ACE 2 is present, it is the preferred angiotensinase. The two
converting enzymes also have different specificities to bradykinin. ACE 2 does not
degrade bradykinin, but degrades des-Arg9-bradykinin at its carboxy terminal amino
acid [Donoghue et al 2000].
Further links between the two systems can be seen in their opposing effects on the
endogenous fibrinolytic system. In cultured endothelial cells, angiotensin II
upregulates and stimulates the release ofPAI-1 [Vaughan et al 1995], although direct
infusion of angiotensin II into the human forearm does not produce any acute change
in either t-PA or PAI-1 antigen release or activity [Labinjoh et al 2001], Bradykinin
infusion on the other hand produces a marked release of t-PA from the endothelium
and has been shown to be one of the most potent stimulants of t-PA release [Labinjoh
et al 2001],
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In addition, further commonalities between the systems can be seen in the fact that
plasma kallikrein may be able to activate prorenin [Derkx et al 1987] and that both
systems have effects on angiogenesis [Emanueli et al 2002; Colman et al 2003],
1.5.1 Renin-angiotensin system manipulation and clinical effects
The outstanding benefits ofACE inhibitor therapy can be seen in a variety of clinical
settings. After showing that it resulted in blood pressure lowering, ACE inhibitor
therapy was tested in patients with heart failure and resulted in improved survival
and improved symptoms [The CONSENSUS Trial Study Group 1987], Since that
time patients at lower and lower risk from atheromatous vascular disease have been
shown to benefit from ACE inhibition (Table 1.2).
Study Name Drug Condition Primary Endpoint
SAVE Captopril Heart Failure Mortality
SOLVD Enalapril Heart Failure Mortality
CONSENSUS Enalapril Heart Failure Mortality
V-HeFT Enalapril Heart Failure Mortality
ISIS -4 Captopril Post MI Mortality
AIRE Ramipril Post MI Mortality
TRACE Trandolapril Post MI Mortality
GISSI - III Lisinopril Post MI Mortality
HOPE Ramipril Vasculopathy CV death, MI, CVA
EUROPA Perindopril Vasculopathy CV death, MI, cardiac arrest
PEACE Trandolapril Vasculopathy CV death, MI, revascularisation
Table 1.2 Some of the trials of ACE inhibition in cardiovascular disease. Ml - myocardial
infarction, CV - cardiovascular, CVA - cerebrovascular accident.
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Although the clinical benefits of ACE inhibitor therapy were initially thought to be
due to blockade of angiotensin II production, it became clear that ACE inhibition had
effects beyond the renin-angiotensin system. It was shown that plasma levels of
angiotensin II returned to pre-treatment levels after chronic ACE inhibitor therapy in
patients with hypertension, suggesting that there were non ACE dependent methods
of angiotensin II generation [Mento and Wilkes 1995]. This led to the hope that
drugs directed at blocking the direct action of angiotensin II on its receptor would
produce greater clinical benefits. Unfortunately in most clinical conditions where
ACE inhibitor therapy has been compared directly with an angiotensin receptor
blocker there has been a trend towards greater morbidity and mortality benefit with
ACE inhibition [ELITE II 2000; OPTIMAAL 2002], although when very high doses
of angiotensin receptor blocking agents were used in patients with heart failure,
valsartan was found to be non inferior to captopril [Pfeffer MA et al 2003], These
results would suggest that the additional benefit ofACE inhibitor therapy may be due
to non angiotensin effects and a major part of this may be due to manipulation of the
kinin system.
1.6 HYPOTHESES
A model to assess endothelium-dependent vasomotion and endogenous t-PA release,
has been published extensively [Newby et al 1997] and will be used to test the
following hypotheses.
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1. The vasodilator actions of bradykinin in healthy volunteers are dependent on the
bradykinin B2 receptor and can be blocked by a novel bradykinin receptor
antagonist B9340.
2. The stimulation of t-PA release from the endothelium by bradykinin in healthy
volunteers is dependent on the bradykinin B2 receptor and can be blocked by a
novel bradykinin receptor antagonist B9340.
3. Endogenous t-PA release is augmented in patients with heart failure treated with
chronic ACE inhibitor therapy.
4. Bradykinin does not contribute to basal vascular tone in healthy volunteers or
patients with heart failure.
5. Bradykinin contributes to basal vascular tone in patients with heart failure treated
with chronic ACE inhibitor therapy.
1.7 AIMS
The aims of the thesis are:
Chapter 3.
In healthy volunteers
• to establish the pharmacodynamics, and tolerability of intra-arterial
bradykinin, an endothelium-dependent vasodilator, in the forearm.
• to determine the tolerability and pharmacodynamics characteristics of B9340,
a novel bradykinin receptor antagonist.
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• to determine the contribution of the endothelial bradykinin receptor to
stimulated t-PA release in vivo in humans.
• to establish the selectivity of B9340, by comparing the vasomotor and
fibrinolytic responses of intra-arterial bradykinin with those of substance P.
Chapter 4.
In patients with heart failure
• to determine the effect of intra-arterial infusion of bradykinin, substance P,
and sodium nitroprusside on vasomotion and t-PA release.




• to confirm that B9340 is a potent and specific bradykinin receptor antagonist
in vivo.
• to establish the role of bradykinin in the maintenance of peripheral vascular
tone.
In patients with heart failure
• to determine whether endogenous bradykinin contributes to the maintenance





• to evaluate the safety and tolerability of intravenous doses of B9340 in
healthy male volunteers using an ascending dose design.
• to demonstrate that the bradykinin receptor antagonist, B9340, inhibits
bradykinin activity in the systemic circulation.
In patients with heart failure
• to determine whether endogenous bradykinin contributes to the







When examining in vivo vascular responses to pharmacological agents in man, drug
administration can be systemic or local. Systemic delivery causes concomitant
effects on organs, such as the brain, kidney and heart, and influences neurohumoral
reflexes through changes in systemic haemodynamics. Because of these confounding
influences, vascular responses cannot be wholly attributed to a direct effect of the
drug on the vascular bed [Webb 1995], Unilateral brachial artery infusions combined
with bilateral venous occlusion plethysmography provides a method of directly
assessing peripheral vascular responses without invoking these systemic influences.
However measuring systemic vascular responses, with a pulmonary artery catheter,
has the benefit of assessing the total effect of the drug on all systemic vascular beds
rather than just a single site and is helpful in confirming systemic vascular responses
are similar to those response evoked locally. Both techniques are employed in the
following studies.
2.2 FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY
The use of venous occlusion plethysmography to measure blood flow in humans was
first described over 90 years ago by Hewlett and van Zwaluwenburg [1909].The
technique is relatively simple with the venous return from the forearm being briefly
interrupted by inflating a cuff, placed around the upper arm, to well above venous
pressure but below diastolic pressure. An inflation pressure of 40 millimetres of
mercury (mmHg) is used for intervals of 10 seconds, followed by 5 seconds of
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deflation, which does not alter arterial inflow and allows venous emptying [Wilkins
and Bradley 1946], The forearm is positioned above the level of the heart to ensure
adequate venous emptying during the period of deflation. This is achieved by resting
the elbows on foam pads and supporting the hands with pillows. The hands are
excluded from the circulation during measurements by the rapid inflation of smaller
cuffs, placed around the wrists, to well above systolic pressure (220 mmHg for
normotensive subjects). The wrist cuffs are inflated for 60 seconds before starting
measurements of flow in order to allow forearm blood flow (FBF) to stabilise
[Kerslake 1949]. The hands are excluded from the system as they contain a large
number of arteriovenous shunts and are very sensitive to temperature variations.
Changes in forearm volume are measured with a plethysmograph, which consists of
mercury in silastic strain gauges [Ensink and Hellige 1981]. The strain gauges are
placed around the widest part of the forearm, and act as resistors connected as one
arm of a Wheatstone bridge [Whitney 1953], Alterations in forearm blood flow
represent alterations in forearm resistance vessels in the muscle and skin. Changes in
forearm volume result in a corresponding change in arm circumference and strain
gauge length, which can be detected as an alteration in electrical resistance of the
gauge, and thus potential difference [Ensink and Hellige 1981]. The gauge length is
made equal to the resting circumference of the limb, so that changes in limb volume
are directly proportional to the changes in resistance [Hokanson et al 2000], This
provides a measure of blood flow to that part of the forearm enclosed by the two
cuffs. This is expressed as millilires per 100 millilitres of forearm volume per
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minute, when electronic calibration is employed [Whitney 1953; Hokanson et al
2000],
Changes in FBF can be reported either in absolute terms or as a percentage of
baseline values. In the following studies, the ratio of FBF in the infused arm to the
control arm (usually around 1) is quoted, as a percentage change from baseline. It has
the theoretical advantage of minimising the influences of small changes in FBF
affecting both arms due, for example, to alteration in sympathetic activation or blood
pressure [Benjamin et al 1995]; the non-infused arm acting as a contemporaneous
control. Percentage changes in the infused FBF are calculated [Benjamin et al 1995;
Webb 1995] as follows:
% Change in blood flow = 100 x (I/NIt - Ifo/NIb) / Ib/NIb
where lb and Nib are the infused and non-infused FBF at baseline (time 0)
respectively, and It and NIt are the infused and non-infused FBF at a given time point
respectively.
2.3 MEASUREMENT OF SYSTEMIC HAEMODYNAMICS
Since the advent of the pulmonary flotation catheter [Swan et al 1970], invasive
measurement of cardiac output (CO) and thus systemic and pulmonary vascular
resistance has changed from a research tool to routine clinical practice in critical care
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areas. The invasive methods of measuring CO are more reliable than non-invasive
measurements using thoracic bioimpedance [Leslie et al 2004].
2.3.1 Cardiac Output
Cardiac output is defined as the amount of blood ejected per unit of time, usually
expressed in litres per minute (L/min). The range of 'normal' CO is difficult to
define because it is influenced by several variables, most importantly body size.
Because CO seems to be predominantly a function of the body's oxygen
consumption or metabolic rate which is thought to correlate best with body surface
area (BSA), it has become customary to express CO in terms of cardiac index
((L/min)/body surface area, m2)).
BSA (m2) = 0.007184 x weight0 425 (kg) x height0 725 (cm)
By using cardiac index rather than CO it greatly reduces variation in range of normal
values. Cardiac output is also affected by age, as metabolic rate reduces in old age,
posture as CO decreases approximately 10% when rising from lying to sitting and
approximately 20% from lying to standing. Cardiac output can also be affected by
temperature, anxiety, heat, and humidity amongst other factors.
There are currently two main methods of measuring CO, the Fick oxygen technique,
sometimes called the 'direct' Fick method, and the indicator dilution method. Both
techniques resemble each other and are based on the theoretical principle described
by Adolph Fick in 1870 [Fick 1870]. The principle is that the amount of a substance
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taken up or released by an organ is the product of its blood flow rate and the
difference in the concentration of the substance between the organ's arterial and
venous blood.
Fick Oxygen or 'Direct' Fick Method
In the Fick oxygen method [Fick 1870], pulmonary blood flow is determined by
measuring the arteriovenous difference of oxygen across the lungs and the rate of
oxygen uptake by blood from the lungs. Assuming no intracardiac shunting, the
pulmonary blood flow is equal to systemic blood flow, thus CO = oxygen
consumption / arteriovenous oxygen difference.
Arteriovenous Oxygen Difference
Measurement of the arteriovenous oxygen difference can be performed by sampling
blood from the pulmonary artery and from the pulmonary veins (although more
commonly left ventricular or systemic arterial blood is used as it is easier to sample),
and measuring the oxygen saturation of the samples. The theoretical oxygen carrying
capacity (TC) is required and can be calculated from Haemoglobin (g/L) x C where
C is a constant normally given the value 1.34 or 1.36, thus
A-V oxygen difference = (%saturationSA x TC) - (%saturationPA x TC)
where SA and PA are systemic artery and pulmonary artery respectively.
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Oxygen Consumption
Measurement of oxygen consumption requires measuring the fractional contents of
oxygen in room air and patients' expired air and volume and rate of inspiration and
expiration, however in actual practice it is often assumed that oxygen consumption
can be predicted from the body surface area thus oxygen consumption is 125 mL/m
or 100 mL/m" for older patients.
Indicator dilution method
The indicator dilution method is a specific application of Fick's general principle
and was introduced by Stewart in 1897 [Stewart 1897]. There are two types of
indicator dilution method, continuous infusion and single bolus methods with single
bolus being most widely used.
Fundamental requirements for the indicator dilution method are
• A bolus injection of non-toxic indicator that mixes completely with blood and
whose concentration can be measured accurately.
• The indicator is neither added to nor subtracted from between injection and
sampling sites.
• Most of the indicator must pass the site of sampling before recirculation
begins.
• The indicator substance must go through a portion of the central circulation
where all the blood of the body becomes mixed.
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Thermodilution method
In the thermodilution method the non-toxic indicator (I) is cold dextrose solution,
the injection site is the right atrium. The temperature of the indicator (Ti) is measured
at injection and the temperature of blood (Tb) is measured in the pulmonary artery as
a function of time (t). Using the following equation cardiac output by thermodilution
(COtd) in mL is given as
CO = Vi(Tb-TD(Si-Ci/Sb-Cb)60
jATb(t)
where Vi is the volume of the injectate (mL), and Sb, Si, Cb and Ci are the specific
gravity and specific heat of blood and injectate respectively. When 5% dextrose is
used as an indicator, (Si-Ci/Sb-Cb) = 1.08.
Potential Errors
Some of the injectate may warm in the catheter after the temperature has been
measured this may give a mild overestimation of CO. In low flow, low output states
warming of the indicator may occur between right atrium and pulmonary artery also
giving a slight overestimation of the CO. The method is also unreliable in the
presence of significant tricuspid regurgitation.
2.3.2 Measurement Of Vascular Resistance
The applicability of laws such as Poiseuille's law derived from steady state fluid
mechanics in assessing vascular resistance is somewhat ambiguous because blood
flow is pulsatile, blood is a nonhomogeneous fluid and the vascular bed is a non-
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linear, elastic, frequency dependent system. In such a system resistance varies
continuously with pressure and flow and is influenced by many factors, such as
inertia, reflected waves, and the phase angle between pulse and flow wave velocities
[O'Rourke 1982; Milnor 1989],
Despite these hurdles, systemic and pulmonary vascular resistance are routinely
calculated in clinical and research settings, from invasive haemodynamic
measurements. The formula generally used for systemic vascular resistance is
Systemic Vascular Resistance = (Mean arterial pressure - Mean right atrial
pressure)/systemic blood flow.
The systemic blood flow is volume flow i.e. cardiac output, expressed in L/min, and
pressures are expressed in mmHg. These equations yield resistance in arbitrary
resistance units expressed in mmHg per L/min, also called Wood units. They can be
converted to metric units expressed as dynes-sec-cm"5 by multiplying the pressure
difference by 80.
The systemic vascular resistance can also be adjusted for body size to give the
systemic vascular resistance index by substituting the cardiac index for the CO in the
previous equation.
The thermodilution method used in the following studies involved a catheter with a
thermistor element proximally and a temperature sensor distally, giving a continuous
42
measure of CO [Ditmyer et al 1995; Bottiger et al 1996]. This avoids the need for
repeated injections of cold dextrose thus, reducing intravenous volume loading
during the study and eliminating intra-operator variability in cold injection technique.
Although termed 'continuous', absolute measurements are taken every 30 seconds
using the 'STAT' mode as this correlates better with the bolus thermodilution
method, especially during acute haemodynamic changes [Lazor MA et al 1997],
2.4 GENERAL
2.4.1 Ethical Considerations
All studies were undertaken in accordance with the Declaration of Helsinki of the
World Medical Association and with the approval of the Local Research Ethics
Committee. The written informed consent of each subject or patient was obtained
before entry into the study.
2.4.2 Subject Preparation
None of the normal healthy volunteers and controls received vasoactive or non¬
steroidal anti-inflammatory drugs in the week before each phase of the study. All
subjects and patients abstained from alcohol for 24 hours and from food, tobacco and
caffeine-containing drinks for at least 5 hours before each study. Studies were
performed in a quiet, temperature controlled room maintained at 21.5-23.5°C.
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2.4.3 Blood Pressure Measurement
During forearm venous occlusion plethysmography, blood pressure was monitored in
the non-infused arm at intervals throughout each study using a semi-automated non¬
invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc,
Tokyo, Japan) [Wiinberg et al 1988].
2.4.4 Brachial Artery Cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-guage steel
needle (Cooper's Needle Works Ltd, Birmingham, UK) under 1% lidocaine
(Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia. The
cannula was attached to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK) and
patency maintained by infusion of saline (0.9%: Baxter Healthcare Ltd, Thetford,
UK) via an IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate
of intra-arterial infusions was maintained constant throughout all studies at 1 mL/min
(Figure 2.1).
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Figure 2.1 Brachial Artery Cannulation, with strain gauge in position around the forearm.
2.4.5 Blood Flow Measurement
Blood flow was measured in the infused and non-infused forearms by venous
occlusion plethysmography as described above. Analogue voltage output from an
EC-4 strain gauge plethysmograph (D.E. Hokanson) was processed by a MacLab®
analogue-to-digital converter and Chart™ v3.3.8 software (AD Instruments Ltd,
Castle Hill, Australia) and recorded onto an iMAC computer (Apple Computers Inc,




Plethysmographic data were extracted from the Chart™ data files and FBF were
calculated for individual venous occlusion cuff inflations by use of a template
spreadsheet (Excel 97; Microsoft). Usually, the last five flow recordings in each
3 minute measurement period were calculated and averaged for each arm. To reduce
the variability of blood flow data, the ratio of flows in the two arms was calculated
for each time point: in effect using the non-infused arm as a contemporaneous




Figure 2.2 Typical plethysmographic data. The upslope of the waveform represents the rate of
forearm swelling. The right arm is the control arm and the left arm is the infused arm during
bradykinin infusion.
46
2.4.7 Pulmonary Artery Catheter Insertion
With aseptic technique, a 8-French venous sheath (Vygon GmbH&Co.KG, Prager
Ring, Aachen, Germany) was inserted via the right femoral vein under local
anaesthesia (Xylocaine; Astra Pharmaceuticals Ltd). Under fluoroscopic screening,
cardiac rhythm monitoring and pressure monitoring, a continuous CO thermodilution
Swan-Ganz catheter (Edwards Lifesciences, Irvine, Calif) was positioned with its
distal tip in the pulmonary arterial tree. To allow for the systemic and pulmonary
haemodynamics to return to a steady basal level after catheter insertion, a 50 minute
infusion of saline at 1 mL/min was given prior to commencing the study. Pulmonary
arterial pressure, pulmonary arterial wedge pressure, and central venous pressure
were recorded at each time point using a Hewlett Packard monitor (U78339A;
Hewlett Packard, Andover, Mass). Continuous cardiac output was recorded using a
Vigilance monitor (Edwards Lifesciences, Irvine, Calif). Heart rate and blood
pressure were measured non-invasively using a semi-automated sphygmomanometer
(U78339A; Hewlett Packard, Andover, Mass).
2.5 FIBRINOLYTIC AND HAEMOSTATIC PARAMETERS
2.5.1 Venous Sampling
In the forearm studies venous cannulae (17-guage) were inserted into large
subcutaneous veins of the antecubital fossa in both arms as described previously
[Plumpton et al 1995], Ten millilitres of blood were withdrawn simultaneously from
each arm and collected into acidified buffered citrate (Biopool® Stabilyte™, Umea,
Sweden) and citrate (Monovette®, Sarstedt, Ntimbrecht, Germany) tubes, and kept on
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ice before being centrifuged at 2,000 g for 30 minutes at 4°C. Platelet free plasma
was decanted and stored at -80°C before assay [Kluft and Verheijen 1990],
In the systemic study venous blood was sampled from the femoral vein sheath. Blood
samples were collected on ice, into lithium heparin (Monovette®) for plasma ACE
activity and ethylene diamine tetraacetic acid tubes (Monovette®) for angiotensin II
analysis and centrifuged immediately, the resulting supernatant stored at -70°C until
assayed.
2.5.2 Plasma Fibrinolytic Parameter Assays
Plasma PAI-1 and t-PA antigen concentrations were determined using an enzyme-
linked immunosorbent assay; Coaliza® PAI-1 [Declerck et al 1988a] and Coaliza®t-
PA [Booth et al 1987] (Chromogenix AB, Molndal, Sweden) respectively. Plasma
PAI-1 and t-PA activities were determined by a photometric method, Coatest® PAI-1
[Wiman et al 1988] and Coaset® t-PA [Gram et al 1987] (Chromogenix AB). Intra-
assay coefficients of variation were 7.0% and 5.5% for t-PA and PAI-1 antigen, and
4.0% and 2.4% for activity, respectively. Inter-assay coefficients of variability were
4.0%, 7.3%, 4.0% and 7.6% respectively. The sensitivities of the assays were 0.5
ng/mL, 2.5 ng/mL, 0.10 IU/mL and 5 AU /mL respectively.
2.5.3 Plasma Neurohormone Analysis
Plasma ACE activity was determined using colorimetric spectrophotometry (SIGMA
Diagnostics, St Louis, Mo) [Holmquist et al 1979], After extraction using Bond Elut
columns (Varian; Harbor City, Calif), plasma angiotensin II (Diasorin, Stillwater,
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Minn) concentrations were determined by radioimmunoassay [Morton and Webb
1985],
2.5.4 HaematocritMeasurement
Haematocrit was determined by capillary tube centrifugation of blood anticoagulated
by ethylene diamine tetraacetic acid.
2.5.5 Data Analysis And Statistics
Estimated net release of t-PA activity and antigen was defined as the product of the
infused FBF (based on the haematocrit, Hct and the infused FBF and the
concentration difference between the infused ([t-PA]jnf) and non-infused arms ([t-
PA]Non-inf)-
Estimated net forearm t-PA release = FBF x (1-Hct) x (t-PAinf. t-PANon-inf)
Data were examined by analysis of variance (ANOVA) with repeated measures, 2-
tailed paired Student's /-test and Student's unpaired t-test using Excel 97 (Microsoft).
All results are expressed as mean ± standard error of the mean. Statistical
significance was taken at the 5% level.
Power calculations were not performed for the forearm studies because when power
calculations are applied to studies with large physiological changes in blood flow, the
sample sizes required are meaningless (normally only one or two subjects are
required if the power calculations are followed.)
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A power calculation was performed for the patient study in chapter six. For a power
of 80% to detect a 3.5 mmHg change in MAP a sample size of 6 was required. We
studied more patients to increase the reliability of the data.
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CHAPTER 3
BRADYKININ RECEPTOR ANTAGONISM AND ENDOTHELIAL
TISSUE PLASMINOTEN ACTIVATOR RELEASE IN HUMANS
3.1 SUMMARY
Objective - We sought to assess pharmacodynamic responses to the bradykinin
antagonist B9340 and to determine the contribution of the endothelial bradykinin
receptor to stimulated t-PA release in humans.
Methods and Results - Bilateral forearm blood flow and plasma fibrinolytic
variables were measured in eight volunteers during 100 minutes of intrabrachial
infusions of saline placebo, B9340 at 4.5 nmol/min, or B9340 at 13.5 nmol/min. On
each occasion, intra-arterial bradykinin (30-3000 pmol/min) and substance P
(4-6 pmol/min) were coinfused for 10 minutes at each dose. To assess the onset and
offset of action, six additional subjects on two occasions received intra-arterial
bradykinin (100 pmol/min) for 60 minutes with a coinfusion of either saline placebo
or B9340 (13.5 nmol/min) for 12 minutes. During placebo infusion, bradykinin and
substance P caused dose-dependent vasodilatation in the infused forearm (p<0.001).
B9340 caused a dose-dependent inhibition of bradykinin-induced forearm
vasodilatation and t-PA release (p<0.001) without affecting substance P-induced
vasodilatation or t-PA release (p<NS). B9340 caused a reversible inhibition of
bradykinin-induced vasodilatation (p<0.001) with a rapid onset and offset of action.
Conclusions - B9340 is a potent, reversible, and selective competitive receptor
antagonist of bradykinin-induced vasodilatation and t-PA release in humans.
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3.2 INTRODUCTION
Bradykinin is an endogenous, vasoactive, nonapeptide mediator involved in many
physiologic processes. It is cleaved from HMW kininogen during the contact phase
of blood coagulation [Reddigari and Kaplan 1988], resulting in endothelium-
dependent vasodilatation and stimulation of t-PA release from human endothelial
cells [van den Eijnden-Schrauwen et al 1995]. It has a brief duration of action
(plasma half-life of 15-30 seconds) owing to its rapid degradation by several
enzymes, principally ACE. Bradykinin appears to contribute to the vascular effects of
ACE inhibitor therapy in hypertension [Gainer et al 1998] and heart failure
[Witherow et al 2001 ].
Bradykinin receptor antagonists have been developed from peptide analogues of
bradykinin. The most widely used bradykinin receptor antagonist is HOE-140, or
icatibant, which demonstrates high selectivity for the Bi receptor. Recently, a third
generation synthetic peptide antagonist of bradykinin, B9340, has been synthesised. It
has a similar chemical structure to HOE-140 and differs by replacement of the a-(2-
indanyl)glycine at position 7 of the molecule with a tetrahydroisoquiniline-3-
carboxylic acid moiety. In comparison with HOE-140, B9340 retains similar potency
of inhibition at the bradykinin Bi receptor (median inhibitory concentration [IC50] of
0.158 nmol/L for both) but has greater inhibition at the B) receptor (IC50 of
lOOOnmol/L and 7.9 nmol/L for HOE-140 and B9340, respectively [Stewart et al
1997],
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The purpose of this study was to assess pharmacodynamic responses to the novel
bradykinin antagonist B9340 and to determine the contribution of the endothelial
bradykinin receptor to stimulated t-PA release in vivo in humans. To assess the
selectivity of B9340, we compared the vasomotor and fibrinolytic responses of
bradykinin with those of substance P, a bradykinin receptor independent,




Fourteen healthy, male volunteers were recruited into the study, which was
performed with approval of the Local Research Ethics Committee, in accordance
with the Declaration of Helsinki (1989) and the written, informed consent of each
subject. Each volunteer was studied at the same time of day and had been fasting for
at least 4 hours before each study. All subjects avoided alcohol for 24 hours and
caffeine containing products for 5 hours before study. No medications or vasoactive
drugs were taken in the 7 days before each study.
3.3.2 Intra-Arterial Administration
All studies were performed in a quiet, temperature controlled (22-25°C) room. On
each occasion, the brachial artery of the non-dominant arm was cannulated with a 27-
gauge needle (Cooper's Needle Works Ltd) after 1% lidocaine local anaesthesia. The
needle was attached to a 16-gauge epidural catheter (Portex Ltd), and needle patency
54
was maintained by an infusion of 0.9% saline at 1 mL/min. The total rate of intra¬
arterial infusions was maintained constant throughout all studies at 1 mL/min.
3.3.3 Forearm Blood Flow and Blood Pressure
Forearm blood flow was measured by mercury in silicone elastomer strain gauge
venous occlusion plethysmography, as previously described [Webb 1995; Petrie et al
2000], Immediately after each FBF measurement, pulse and blood pressure were
measured non-invasively in the non-infused arm throughout each study with a semi-
automated digital sphygmomanometer (UA-731, A&D Engineering). Mean arterial
pressure was defined as the diastolic blood pressure plus one-third of the pulse
pressure.
3.3.4 Drugs
Pharmaceutical grade B9340 (Clinalfa AG), substance P (Clinalfa), and bradykinin
(Clinalfa) were dissolved in 0.9% saline before infusion. All solutions were freshly
prepared on the day of study. The doses of bradykinin were based on previous
studies [Labinjoh et al 2000] and the doses of B9340 based on the dose of FIOE-140
given in other studies [Cockroft et al 1994a] as it has a similar efficacy at the B2
receptor.
3.3.5 Venous Sampling and Assays
Venous cannulas (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossa in both arms, as described previously [Newby et al 1997]. Ten
millilitres of blood were withdrawn simultaneously from each arm and collected into
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acidified, buffered citrate (Biopool Stabilyte) and citrate (Monovette, Sarstedt) tubes
and kept on ice before being centrifuged at 2,000 g for 30 minutes at 4°C. Platelet
free plasma was decanted and stored at -80°C before assay. Plasma t-PA antigen and
activity concentrations were determined by ELISA (Coaliza t-PA, Chromogenix AB)
and a photometric method (Coatest t-PA, Chromogenix AB), respectively, as
described previously [Newby et al 1998].
3.3.6 Study Design
Protocol 1: Efficacy and Selectivity ofB9340
Eight healthy, male volunteers attended on three occasions at least 1 week apart.
After 30 minutes equilibration with saline infusion, intra-arterial placebo (0.9%
saline), B9340 at 4.5 nmol/min, or B9340 at 13.5 nmol/min was infused for
100 minutes on separate occasions in a randomised, double-blind, ascending dose
design. Placebo/B9340 was coinfused with saline for 10 minutes; bradykinin at 30,
300, and 3,000 pmol/min for 10 minutes at each dose; and after a 30 minute saline
infusion, substance P at 4, 8, and 16 pmol/min for 10 minutes at each dose. Forearm
blood flow and mean arterial pressure were measured every 10 minutes for the
duration of the study. Venous samples were obtained at baseline, after 10 minutes of
B9340/placebo infusion, and after each dose ofbradykinin and substance P.
Protocol 2: Onset and Offset ofB9340 Action
Six additional healthy, male volunteers attended on two occasions at least 1 week
apart. After 30 minutes equilibration with saline infusion, intrabrachial bradykinin
was infused at 100 pmol/min for 60 minutes. After 12 minutes of bradykinin infusion,
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B9340 (Clinalfa) at 13.5 nmol/min or placebo (saline vehicle) was coinfused for
12 minutes in a randomised, double-blind manner. Forearm blood flow and mean
arterial pressure were measured every 6 minutes for the duration of the study.
3.3.7 Data Analysis and Statistics
Plethysmographic data were extracted from the software (Chart) data files, and FBF
was calculated for individual venous occlusion cuff inflations by use of a template
spreadsheet (Excel 97, Microsoft). The last five flow recordings in each 3 minute
measurement period were calculated and averaged for each arm. The effective dose,
causing a 100% increase in FBF (EDioo), was calculated to assess the degree of
bradykinin antagonism. The percentage increase in blood flow was determined from
the ratio of the FBF's, as described previously [Petrie et al 2000].
Estimated net release of t-PA antigen and activity was defined as the product of the
infused FBF (based on the haematocrit [Hct] and the infused FBF), and the
concentration difference between the infused (t-PAi„f) and non-infused forearms (t-
PAiMon-inf)-
Estimated net t-PA release = FBF x (1-HCt) x (t-PAinf- t-PANon-inf)
Data were examined, where appropriate, by ANOVA with repeated measures and
2-tailed, paired Student's t-test with commercially available software (Excel 97). All




The infusions were well tolerated with no major adverse events. There were no
significant changes in FBF in the non-infused arm, heart rate, or blood pressure
during the infusions.
3.4.1 Protocol 1: Efficacy and Selectivity of B9340
Subjects were aged 25±5 years with a body mass index of 22±2 kg/m .
Forearm Blood Flow
Baseline blood flow during saline infusion was 2.0±0.2 mL • 100 mL"1 • min"1 in the
infused arm and 2.0±0.1 mL • 100 mL"1 • min"1 in the non-infused arm. In comparison
with placebo, B9340 infusion alone caused no significant change in the infused FBF
from baseline at either dose (placebo, -7.4±3.7%; B9340 at 4.5 nmol/min, 8.1±7.6%;
and B9340 at 13.5 nmol/L, 3.8±5.5%; ANOVA, (p=0.8). During placebo infusion,
bradykinin and substance P caused dose-dependent vasodilatation in the infused
forearm (ANOVA, p<0.001 for both; Figure 3.1). At doses of 4.5 and 13.5 nmol/min,
B9340 caused 7-fold and 18-fold increases in the EDioo for bradykinin, respectively
(ANOVA, p<0.001 for both; Figure 3.1). In contrast, B9340 had no effect on
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Figure 3.1 Infused FBF during substance P (left) and bradykinin (right) infusion with saline
placebo (circles), B9340 at 4.5 nmol/min (squares), and B9340 at 13.5 nmol/min (triangles).
PcO.OOl, ANOVA, for all blood flow responses; /?<0.001, ANOVA, for comparisons between
saline placebo and B9340 administration for bradykinin infusion (right) only.
EstimatedNet t-PA Release
Baseline plasma t-PA antigen and activity concentrations during saline infusion were
3.4±0.4 ng/mL and 1.3±0.3 IU/mL in the infused arm and 3.6±0.3 ng/mL and
1.3±0.3 IU/mL in the non-infused arm, respectively. B9340 infusion alone produced
no change in plasma t-PA antigen or activity (ANOVA, p=0.9). Both bradykinin and
substance P produced a dose-dependent increase in plasma t-PA antigen and activity
concentrations in the infused forearm (ANOVA, p<0.001). Both doses of B9340
completely inhibited t-PA antigen and activity release at 300 pmol/min bradykinin
and reduced t-PA antigen and activity release at 3,000 pmol/min by 4- to 8-fold
(ANOVA, p<0.001 for both doses; Figure 3.2). There was no effect of B9340 on
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Figure 3.2 Estimated net t-PA antigen (closed symbols, top) and activity (open symbols, bottom)
release during substance P (left) and bradykinin (right) infusion with saline placebo (circles),
B9340 at 4.5nmol/min (squares), and B9340 at 13.5 nmol/min (triangles). P<0.05, ANOVA, for all
t-PA responses; /K0.001, ANOVA, for comparisons between saline placebo and B9340
administration for bradykinin infusion (right) only.
3.4.2 Protocol 2: Onset andOffset of B9340 Action
• 2
Subjects were aged 30±2 years with a body mass index of 21±2 kg/nr. Baseline
blood flow during saline infusion was 3.4±1.0 mL • 100 mL"1 • min"1 in the infused
arm and 2.7±0.6 mL • 100 mL"1 • min"1 in the non-infused arm. Bradykinin infusion
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caused a 288±7% increase in the infused FBF that was sustained for 60 minutes
(ANOVA, p<0.001; Figure 3.3). Compared with placebo, B9340 coinfusion caused a
rapid onset and offset of inhibition of bradykinin-induced vasodilatation (ANOVA,
p<0.001; Figure 3.3).
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Figure 3.3 Infused arm FBF with bradykinin infusion (black bar; 100 pmol/min) during
placebo (open circles) or B9340 (closed circles; 13.5 nmol/min) co-administration (grey bar).
3.5 DISCUSSION
We have confirmed our earlier findings [Labinjoh et al 2001; Witherow et al 2002]
that intrabrachial bradykinin infusion causes marked forearm vasodilatation and
endothelial t-PA release. We have demonstrated that B9340 is a potent and
competitive antagonist of bradykinin-induced vasodilatation and endothelial t-PA
release in vivo in humans. B9340 appears to be a selective and reversible bradykinin
receptor antagonistwith a rapid onset and offset of action.
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B9340 caused dose-dependent inhibition of bradykinin-induced vasodilatation and
t-PA release, suggesting that it acts as a competitive receptor antagonist and that both
vascular effects are mediated through bradykinin receptors. Previous clinical studies
[Cockcroft et al 1994a; Brown et al 2000] have used systemic intravenous
administration of the selective B2 receptor antagonist HOE-140, combined with
intrabrachial bradykinin infusions. However, systemic drug administration might
have ancillary effects, and the antagonist effects of HOE-140 could have been
mediated through intermediary pathways. In contrast, here we have demonstrated a
direct, local, dose-dependent inhibition of the vascular actions of bradykinin with
intra-arterial infusions of B9340. Moreover, those previous studies of systemic HOE-
140 administration either lacked a control vasodilator [Cockcroft et al 1994a] or used
the endothelium independent vasodilator sodium nitroprusside [Brown et al 2000].
We have more rigorously demonstrated the selectivity of bradykinin antagonism by
B9340 through comparison with the tachykinin substance P, which acts through the
endothelial neurokinin type-1 receptor to cause endothelium-dependent
vasodilatation [Newby et al 1999a] and t-PA release. The antagonist action of B9340
cannot, therefore, be attributed to a nonspecific effect on the vascular endothelium
and appears to be selective for bradykinin receptors.
Bradykinin is thought to exert its vasodilatory effects by activating the B2 receptor on
vascular endothelium. This results in release of nitric oxide [Cockcroft et al 1994b;
O'Kane et al 1994] and endothelium derived hyperpolarising factor to produce
vasorelaxation [Beny et al 1987; Nakashima et al 1993], However, although
inhibition of nitric oxide synthase with A^-monomethyl-L-arginine attenuates the
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vasodilatation to bradykinin, it does not affect endothelial t-PA release [Brown et al
2000], This would suggest that bradykinin stimulated t-PA release is mediated
through a nitric oxide synthase independent pathway and that the endothelium
regulates blood flow and t-PA release through distinct pathways. Indeed, we have
recently demonstrated that direct, local, endothelial t-PA release can be induced by
tumour necrosis factor-a In the absence of alterations in blood flow in the human
forearm [Chia et al 2003b]. Thus, bradykinin-induced t-PA release appears to be
dependent on the endothelial bradykinin receptors and to act through a second-
messenger pathway that is distinct from the regulation of vasomotion.
B9340 had no effect on basal FBF or plasma t-PA concentrations, suggesting that in
healthy humans, bradykinin does not contribute to the basal maintenance of vascular
tone or t-PA release. However, this does not preclude a potential role for bradykinin
in pathophysiologic conditions, such as inflammation [Raidoo et al 1997], or
instances where ACE inhibitor therapy is used [Witherow et al 2001; Pretorius et al
2003],
Although B9340 antagonises the B2 receptor at concentrations nearly two orders of
magnitude greater than those at the Bi receptor, B9340 might still produce some
blockade of the B) receptor. The Bi receptor was previously thought to be inactive in
the vascular system unless upregulated during inflammation. Raidoo et al [1997]
have recently shown that Bj receptors are present in large numbers on the vascular
endothelium and are further upregulated around atherosclerotic plaques. However,
the functional significance of the Bi receptor on the endothelium is unknown, and the
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work by Brown et al [2000] using HOE-140 would suggest that the observed effects
are mediated principally through blockade of the B2 receptor.
3.6 CONCLUSIONS
B9340 is a potent, reversible, and selective competitive inhibitor of bradykinin-
induced vasodilatation and t-PA release in humans. This compound is a potentially
useful investigational tool in dissecting out the physiologic and pathophysiologic role
of bradykinin in vivo in humans.
64
CHAPTER 4
MARKED BRADYKININ-INDUCED TISSUE PLASMINOGEN
ACTIVATOR RELEASE IN PATIENTS WITH HEART FAILURE
MAINTAINED ON CHRONIC ACE INHIBITOR THERAPY
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SUMMARY
Objective - Bradykinin is a potent endothelial cell stimulant that causes
vasodilatation and t-PA release. In large scale clinical trials, ACE inhibitor therapy
prevents ischaemic events. The aim of the present study was to assess the
contribution of ACE inhibitor therapy to bradykinin-induced t-PA release in patients
with heart failure secondary to ischaemic heart disease.
Methods and Results - Nine patients with symptomatic heart failure were evaluated
on two occasions: during and following 7 day withdrawal of long-term ACE
inhibitor therapy. Forearm blood flow was measured using bilateral venous occlusion
plethysmography. Intrabrachial bradykinin (30-300 pmol/min), substance P (2-8
pmol/min), and sodium nitroprusside (1-4 pmol/min) were infused, and venous blood
samples were withdrawn from both forearms for estimation of fibrinolytic variables.
On both study days, bradykinin and substance P caused dose-dependent
vasodilatation and release of t-PA from the infused forearm (p<0.05 by ANOVA).
Long-term ACE inhibitor therapy caused an increase in forearm vasodilatation
(p<0.05 by ANOVA) and t-PA release (p<0.001 by ANOVA) during bradykinin, but
not substance P, infusion. Maximal local plasma t-PA activity concentrations
approached 100 IU/mL, and maximal forearm protein release was -4.5 ug/min.
Conclusions - Long-term ACE inhibitor therapy augments bradykinin-induced
peripheral vasodilatation and local t-PA release in patients with heart failure due to
ischaemic heart disease. Local plasma t-PA activity concentrations approached those
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seen during systemic thrombolytic therapy for acute myocardial infarction. This may
contribute to the primary mechanism of the anti-ischaemic effects associated with
long-term ACE inhibitor therapy.
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4.2 INTRODUCTION
Bradykinin is a potent endothelium-dependent vasodilator that has a brief duration of
action due to its rapid degradation by ACE. In addition to acting as an inflammatory
mediator, bradykinin is closely involved in fibrinolytic and coagulation cascades.
During the contact phase of blood coagulation, it is released after cleavage of HMW
kininogen by kallikrein [Reddigari and Kaplan 1988], It is also a potent stimulant for
the release of t-PA from the endothelium [Labinjoh et al 2001]. Thus, when plaque
rupture or erosion activates the intrinsic coagulation pathway, liberation of
bradykinin may represent an important negative feedback loop in which bradykinin-
induced t-PA release inhibits intravascular thrombus formation.
Large scale clinical trials of patients with heart failure or ischaemic heart disease
indicate a reduction in recurrent infarction rates with ACE inhibitor therapy [The
Heart Outcomes Prevention Evaluation Study Investigators 2000], The mechanisms
underlying this anti-ischaemic benefit may relate, in part, to the effects on
endogenous fibrinolysis. Inhibition of ACE enhances bradykinin-induced
vasodilatation and endothelial t-PA release in healthy volunteers [Labinjoh et al
2001]. However, to date, there has been no assessment of the effect of long-term
ACE inhibition on acute endogenous t-PA release in patients with heart failure or
ischaemic heart disease. Therefore, the aim of this study was to determine whether
long-term ACE inhibition potentiates acute t-PA release in patients with heart failure




Nine patients with New York Heart Association (NYHA) functional class II or III
heart failure secondary to ischaemic heart disease participated in the study, which
was undertaken with the approval of the Local Research Ethics Committee, in
accordance with the Declaration of Helsinki (1989), and each subject gave written,
informed consent. All subjects had been maintained on a maximally tolerated dose of
an ACE inhibitor for more than 6 months, and they abstained from alcohol for
24 hours and from food and caffeine containing drinks for at least 4 hours before
each study.
4.3.2 Measurements
Forearm bloodflow and haemodynamics
Blood flow was measured in both forearms by venous occlusion plethysmography
using mercury in silastic strain gauges applied to the widest part of the forearm, as
previously described [Newby et al 1997; Labinjoh et al 2001]. Blood pressure and
heart rate were monitored in the non-infused arm at intervals throughout each study
by using a semi-automated non-invasive oscillometric sphygmomanometer (Takeda
UA 751, Takeda Medical Inc., Tokyo, Japan).
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Assays
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossa in both arms. Ten to twenty millilitres of blood were withdrawn
simultaneously from each arm and collected into acidified buffered citrate (Biopool
Stabilyte, Umea, Sweden; for t-PA assays) and citrate (Monovette, Sarstedt,
Niimbrecht, Germany; for PAI-1 assays) tubes and kept on ice before being
centrifuged at 2,000 g for 30 minutes at 4°C. Platelet free plasma was decanted and
stored at -80°C before assay. Plasma t-PA and PAI-1 antigen and activity
concentrations were determined using enzyme-linked immunosorbent assays and a
photometric method, as previously described [Newby et al 1997; Labinjoh et al
2001].
4.3.3 Study design
Patients were evaluated at 9 a.m. on two occasions: during and after 7 day
withdrawal of long-term ACE inhibitor therapy. On the appropriate study day, oral
ACE inhibitor therapy was administered at 8 a.m. The brachial artery of the non-
dominant arm was cannulated with a standard 27-gauge steel wire needle (Cooper's
Needle Works Ltd., Birmingham, UK) under local anaesthesia. The total rate of
intra-arterial infusions was maintained constant at 1 mL/min, and FBF was measured
every 10 minutes throughout all studies. Intrabrachial infusions of substance P
(Clinalfa AG, Laufelfmgen, Switzerland) at 2, 4, and 8 pmol/min, bradykinin
(Clinalfa AG) at 30, 100, and 300 pmol/min, and sodium nitroprusside (David Bull
Laboratories, Warwick, UK) were given at 1,2, and 4 pg/min for 10 minutes at each
70
dose in a randomised order [Labinjoh et al 2001]. Saline was infused for 30 minutes
before the substance P, sodium nitroprusside, and bradykinin infusions.
4.3.4 Data analysis and statistics
Forearm blood flow was calculated for individual venous occlusion cuff inflations, as
previously described [Newby et al 1997; Labinjoh et al 2001], Estimated net release
of t-PA activity and antigen was previously defined as the product of the infused
FBF (based on the mean haematocrit and infused FBF) and the concentration
difference between the infused and non-infused arms [Newby et al 1997; Labinjoh et
al 2001]. Data were examined, where appropriate, by ANOVA with repeated
measures and the 2-tailed paired Student Mest, using Microsoft Excel 97. All results
are expressed as the mean value ± SEM. Statistical significance was set at the 5%
level.
4.4 RESULTS
Patient characteristics are shown in Table 4.1. After withdrawal of ACE inhibitor
therapy, baseline mean arterial pressure appeared to rise, but this was not statistically
significant. There were no significant changes in heart rate, blood pressure or non-

































Table 4.1 Patient characteristics (n = 9). Data are presented as the number of patients or
mean value ± SEM. *Diastolic pressure + one-third of pulse pressure. ACE - angiotensin-
converting enzyme; LVEDD - left ventricular end diastolic diameter; Visit 1 - during long-








































Figure 4.1 Effect of intra-arterial bradykinin and substance P infusions on blood flow and plasma
tissue-type plasminogen activator (t-PA) antigen (solid lines) and activity (dashed lines)
concentrations in the infused (solid symbols) and non-infused (open symbols) arms in the presence
(left) or absence (right) of angiotensin-converting enzyme (ACE) inhibition. *p < 0.05 by analysis
of variance (ANOVA). fp < 0.001 by ANOVA for long-term ACE inhibition versus no ACE
inhibition.
4.4.1 Forearm blood flow responses
Sodium nitroprusside (data on file), substance P, and bradykinin caused dose-
dependent forearm vasodilatation during each study visit (ANOVA for blood flow
response, p<0.001 for all; n=9 at baseline and with the three doses, degree of
freedom [d.f.] =3) (Figure 4.1). In the presence of long-term ACE inhibition, forearm
vasodilatation was augmented during bradykinin (ANOVA for ACE inhibition
versus no ACE inhibition, p<0.05; n=9 for blood flow at baseline and with the three
doses, d.f.=l), but not substance P or sodium nitroprusside (p=NS) infusion.
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4.4.2 Plasma fibrinolytic variables
Bradykinin and substance P caused dose-dependent increases in plasma t-PA antigen
and activity concentrations in the infused arm (ANOVA for plasma t-PA
concentrations, p<0.05 for all; n=9 at baseline and with the three doses, d.f=3)
(Figure 4.1). Plasma t-PA antigen and activity concentrations were significantly
augmented during bradykinin (ANOVA for ACE inhibition versus no ACE
inhibition, p<0.001; n=9 for plasma t-PA concentrations at baseline and with the
three doses, d.f.=l), but not substance P (p=NS) infusion in the presence of long-
term ACE inhibition.
Basal plasma PAI-1 antigen concentrations were lower in the presence (38±6 ng/mL)
than in the absence (48±7 ng/mL) of ACE inhibitor therapy (paired /-test for ACE
inhibition versus no ACE inhibition, p<0.02; n=9 for plasma PAI-1 concentrations,
d.f.=l). Bradykinin and substance P administration had no effect on plasma PAI-1
concentrations.
4.4.3 Release of tissue plasminogen activator
Substance P and bradykinin caused dose-dependent increases in the plasma t-PA
antigen and activity concentration differences between the forearms, as well as the
estimated net release of t-PA antigen and activity during each study visit (ANOVA
for t-PA release, p<0.01 for all; n=9 for t-PA release or concentration difference at
baseline and with the three doses, d.f.=3) (Figure 4.2). During ACE inhibition, there
was a massive increase in bradykinin-induced (ANOVA for ACE inhibition versus
no ACE inhibition, p<0.001; n=9 for t-PA release at baseline and with the three
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doses, d.f.=l) (Figure 4.2), but not substance P induced (p=NS), release of t-PA
antigen and activity (increases in the area under the curve of 520% and 877%,
respectively). Post-hoc analysis identified no significant effect of other concomitant
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Figure 4.2 Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid
lines) and activity (dashed lines) during bradykinin (right) and substance P (left) infusions in the
presence (solid circles) or absence (open circles) of angiotensin-converting enzyme (ACE)
inhibition, p < 0.01 by analysis of variance (ANOVA) for all responses. *p < 0.001 by ANOVA
for lona-term ACE inhibition versus no ACE inhibition.
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4.5 DISCUSSION
For the first time, to the best of our knowledge, we have shown that in patients with
heart failure secondary to ischaemic heart disease, long-term ACE inhibition
markedly potentiates bradykinin-induced endogenous t-PA release from the
endothelium. However, this potentiation appears to be specific to bradykinin,
because ACE inhibition did not influence substance P-induced t-PA release. These
findings suggest that the beneficial clinical and vascular effects of ACE inhibition
may be partly mediated through the acute local augmentation of bradykinin-induced
t-PA release.
4.5.1 Magnitude of t-PA release
Long-term ACE inhibition produced a massive augmentation of bradykinin-induced
t-PA release across the forearm vascular bed. Although these doses of bradykinin are
supra physiological, the approximate 5-fold increase in t-PA antigen release and the
-20% reduction in plasma PAI-1 antigen concentrations led to the approximate 9-
fold increase in the release of active t-PA. Our group has previously shown that
bradykinin-induced t-PA release is augmented by ACE inhibition in healthy
volunteers, but this was modest at approximately 2-fold only [Labinjoh et al 2001].
The dramatic potentiation of active t-PA release in the present study is exemplified
by the observation that the maximal local forearm concentrations of active t-PA (99
IU/mL at 300 pmol/min of bradykinin) approached those observed during systemic
thrombolysis during acute myocardial infarction (100 to 1,000 IU/mL) [Koster et al
1991], Moreover, it also underscores the large capacity of the endothelium to release
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t-PA quickly, up to 4.5 pg or 16,000 IU/min from the infused forearm at 300
pmol/min of bradykinin. Indeed, using intrabrachial substance P infusions, we have
previously demonstrated substantial and sustained release of t-PA for up to 2 hours
[Newby et al 1998].
Minai et al [2001] have recently reported that ACE inhibition produces an
approximate 2-fold increase in bradykinin-induced t-PA release in the coronary
circulation of patients with atypical chest pain and angiographically normal coronary
arteries. This is consistent with our previous findings in the peripheral circulation of
healthy volunteers [Labinjoh et al 2001] and suggests that comparable endothelial
fibrinolytic effects exist between the peripheral and coronary circulations [Newby et
al 2001b], The present study extends these previous findings, because we have
demonstrated a more marked augmentation of peripheral t-PA release in patients
with heart failure secondary to ischaemic heart disease.
4.5.2 Mechanism of bradykinin-induced t-PA release
In keeping with our previous work [Labinjoh et al 2001] and that by others
[Benjamin et al 1989], ACE inhibition augmented the vasodilatation induced by
bradykinin but did not affect the vasodilatation or t-PA release produced by
substance P. This suggests that the effect ofACE inhibition does not appear to reflect
a generalised enhancement of vascular function but is specific to bradykinin. Brown
et al [2000] and Gainer et al [2001] have previously investigated the mechanism of
bradykinin-induced t-PA release in the human forearm. Bradykinin induces t-PA
release through a B2 receptor dependent, nitric oxide synthase independent, and
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cyclooxygenase independent pathway [Brown et al 2000]. Brown et al [2000] have
suggested that bradykinin-induced t-PA release may be caused by an endothelium-
derived hyperpolarising factor, although other mediators may be involved. This
group has also described a potential interaction between the vascular responses to
bradykinin and the ACE gene insertion/deletion polymorphism [Gainer et al 2001],
We have not explored this interaction because of the small sample size of our study,
but this may markedly influence the fibrinolytic response to long-term ACE
inhibition in patients with heart failure or vascular disease, and it requires further
investigation.
Inflammation plays an important role in the pathogenesis of heart failure [Gottdiener
et al 2000], with elevated plasma concentrations of circulating cytokines such as
tumour necrosis factor-a [Feldman et al 2000], Bradykinin receptor expression is
altered by ACE inhibition [Miyamoto et al 2000; Marin-Castano et al 2002],
inflammation [Marceau 1995], and chronic heart failure [Witherow et al 2001], ACE
inhibitor therapy alters the B2 receptor to have high and low affinity sites for
bradykinin binding, and B1 receptor expression is upregulated in arteries by ACE
inhibition and these findings may partly explain the proportionately greater and
massive release of t-PA from the endothelium [Miyamoto et al 2000; Marin-Castano
et al 2002],
4.5.3 Endothelial function, endogenous fibrinolysis, and heart failure
The endothelium plays a vital role in the control of blood flow, haemostasis,
fibrinolysis, and inflammation. Consequently, the maintenance and regulation of
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tissue perfusion critically depends on the integrity of endothelial function and the
release of potent endothelium-derived factors. After the seminal work of Furchgott
and Zawadski [1980], it has been widely recognised that an array of mediators can
influence vascular tone through endothelium-dependent actions, and there is now
extensive evidence of abnormal endothelium-dependent vasomotion that is reversed
by ACE inhibition in patients with heart failure [Drexler et al 1995; Varin et al
2000], However, although endothelium-dependent vasomotion is important, it may
not be representative of other aspects of endothelial function, such as the regulation
of endogenous fibrinolysis.
Tissue plasminogen activator is a serine protease that regulates the degradation of
intravascular fibrin and is released from the endothelium through the translocation of
a dynamic intracellular storage pool. If endogenous fibrinolysis is to be effective,
then the rapid mobilisation of t-PA from the endothelium is essential, because
thrombus dissolution is much more effective if t-PA is incorporated during, rather
than after, thrombus formation [Fox et al 1984], This dynamic aspect of endothelial
function and fibrinolytic balance may be directly relevant to the pathogenesis of
atherothrombosis and is not necessarily reflected by the basal plasma concentrations
of t-PA [Jern et al 1999; Newby et al 1999; Newby et al 2001a],
4.5.4 Clinical relevance
The endogenous fibrinolytic system can have important clinical effects, as
exemplified by the observation that in one-third of patients with an acute myocardial
infarction, the infarct related artery spontaneously reperfuses within 12 hours
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[DeWood et al 1980; Armstrong et al 1989; Rentrop et al 1989], Moreover, low
fibrinolytic activity is associated with an increased risk of in young men [Meade et al
1993] and predicts which patients with unstable angina will develop myocardial
infarction [Munkvad et al 1990]. Clinical studies of patients with unstable angina
have also indicated that there is an enhanced activation of the kallikrein system and
that bradykinin release is increased [Hoffmeister et al 1995], Given this
augmentation of bradykinin generation and activation of the intrinsic coagulation
pathway in acute coronary syndromes, ACE inhibition may have major beneficial
effects on the acute local fibrinolytic balance by markedly enhancing bradykinin-
induced t-PA release in areas of intravascular thrombus formation. This is consistent
with the observation that ACE inhibition improves the basal fibrinolytic balance
[Wright et al 1994; Vaughan et al 1995b] and reduces myocardial troponin release in
patients with acute coronary syndromes [Kennon et al 2001],
4.6 CONCLUSIONS
Long-term angiotensin-converting enzyme inhibitor therapy augments bradykinin-
induced peripheral vasodilatation and local t-PA release in patients with heart failure
due to ischaemic heart disease. Local plasma t-PA activity concentrations
approached those seen during systemic thrombolytic therapy for acute myocardial
infarction. This may contribute to the primary mechanism of the anti-ischaemic
effects associated with long-term ACE inhibitor therapy.
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CHAPTER 5
BRADYKININ CONTRIBUTES TO THE VASODILATOR
EFFECTS OF CHRONIC ACE INHIBITION
IN PATIENTS WITH HEART FAILURE
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5.1 SUMMARY
Background - Bradykinin, an endogenous vasodilator peptide, is metabolised by
ACE. The aims of the present study were to determine the doses of B9340, a
bradykinin receptor antagonist, that inhibit vasodilatation to exogenous bradykinin
and to assess the contribution of bradykinin to the maintenance of basal vascular tone
in patients with heart failure receiving chronic ACE inhibitor therapy.
Methods and Results - Forearm blood flow was measured using bilateral venous
occlusion plethysmography. On three occasions in a double-blind randomised
manner, eight healthy volunteers received intrabrachial infusions of placebo or
B9340 (at 4.5 and 13.5 nmol/min). On each occasion, placebo or B9340 was
coinfused with bradykinin (30-3,000 pmol/min) and substance P (4-16 pmol/min).
B9340 caused no change in basal FBF but produced dose-dependent inhibition of the
vasodilatation to bradykinin (p<0.001) but not substance P. The effects of bradykinin
antagonism were studied in 17 patients with NYHA grade II-IV heart failure
maintained on chronic ACE inhibitor therapy. Incremental doses of B9340, but not
HOE-140, produced a dose-dependent vasoconstriction (p<0.01). After withdrawal
of ACE inhibitor therapy, B9340 produced no significant change in FBF. After
reinstitution of therapy, B9340 again resulted in vasoconstriction (p<0.03).
Conclusions - B9340 is a potent and selective inhibitor of bradykinin-induced
vasodilatation. Bradykinin does not contribute to the maintenance of basal peripheral
arteriolar tone in healthy humans or patients with heart failure but contributes to the
vasodilatation associated with chronic ACE inhibitor therapy in patients with heart
failure via the Bi receptor.
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5.2 INTRODUCTION
Patients with heart failure have a reduced cardiac reserve that is associated with
neurohumoral activation of the renin-angiotensin-aldosterone system and peripheral
vasoconstriction. Through blockade of angiotensin I conversion, ACE inhibitor
therapy limits the generation of angiotensin II, thereby reducing the associated
vasoconstriction and sodium and water retention. It has been widely established that
ACE inhibitor therapy has major therapeutic benefits in patients with heart failure
[Cohn et al 1991; The AIRE investigators 1993], which include improvements in
morbidity, exercise capacity, and mortality (The CONSENSUS Trial Study Group
1987; Cohn et al 1991], The administration of ACE inhibitor therapy in these patients
causes systemic vasodilatation [Flapan et al 1992] that has been attributed to the loss
of angiotensin II mediated vasoconstriction. However, it is unknown whether the
vasodilatation associated with ACE inhibitor therapy may in part relate to the
concomitant blockade of bradykinin degradation.
Bradykinin is a potent endothelium-dependent vasodilator [(Cherry et al 1982;
Cockcroft et al 1994] that has a brief duration of action (plasma half-life of 15-
30 seconds) because of its rapid degradation by ACE. Indeed, ACE breaks down
>95% of bradykinin in a single passage through the pulmonary circulation [Bonner et
al 1992]. Exogenous administration of bradykinin induces vasodilatation of
epicardial coronary [Groves et al 1995; Kuga et al 1997] and resistance arteries in
humans, which is mediated in part by nitric oxide [O'Kane et al 1994] and
endothelium-derived hyperpolarising factor [Honing et al 2000]. The local and
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systemic vascular effects of exogenous bradykinin administration can be enhanced by
ACE inhibition [Benjamin et al 1989; Bonner et al 1992], In hypertensive patients
and sodium deplete volunteers, Gainer et al [1998] have shown that systemic
infusion ofHOE-140 (icatibant), a highly selective bradykinin B2 receptor antagonist,
attenuated the hypotensive effects of captopril and resulted in a similar reduction in
blood pressure to losartan, an angiotensin II type-1 receptor blocker. This suggests
that some of the short-term hypotensive effects of ACE inhibition are mediated by
augmentation of endogenous bradykinin. This study has, however, been criticised for
its design, because the observed pressor effect may have been attributable to the
differing pharmacokinetic profiles of losartan and captopril [Azizi 1999], Moreover,
it did not address other pertinent issues, such as the effect of chronic ACE inhibition,
or the potential role ofthe Bi receptor.
When examining in vivo vascular responses in humans, systemic drug administration
causes concomitant effects on organs, such as the brain, kidney, and heart, and
influences neurohumoral reflexes through changes in systemic haemodynamic
parameters. Because of these influences, vascular responses cannot be wholly
attributed to a direct effect of the drug on blood vessels [Benjamin et al 1989; Webb
1995]. In contrast, the use of bilateral FBF measurements, with unilateral brachial
artery infusion of vasoactive drugs at sub systemic, locally active doses, provides a
powerful and reproducible method of directly assessing vascular responses in vivo.
This technique has been used to demonstrate the major contribution of nitric oxide
and endothelin-1 to the maintenance of basal peripheral vascular tone [Valance et al
1989; Haynes and Webb 1994] and to predict the pressor and depressor effects of
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systemic nitric oxide inhibition and endothelin receptor antagonism, respectively
[Haynes et al 1993; Haynes et al 1996].
Several peptidic and nonpeptidic bradykinin receptor antagonists are presently under
development. However, to date, there has been no assessment of the combined
contribution of Bi and B2 receptors to basal vascular tone in patients with heart
failure maintained on chronic ACE inhibitor therapy. B9340, a peptidic analogue of
HOE-140, has inhibitory activity against both Bi and B2 receptors [Stewart et al
1997] and has recently become available for use in clinical studies. Therefore, the
aims of the present study were, first, to confirm that B9340 is a potent and specific
bradykinin receptor antagonist in vivo in humans; second, to establish the role of
bradykinin in the maintenance of peripheral vascular tone in healthy volunteers; and,
third, to determine whether endogenous bradykinin contributes to the maintenance of
basal peripheral vascular tone in patients with heart failure maintained on chronic
ACE inhibitor therapy using both the selective and nonselective bradykinin receptor
antagonists, HOE-140 andB9340, respectively.
5.3 METHODS
5.3.1 Study Subjects
The protocols were performed with the approval of the Local Research Ethics
Committee in accordance with the Declaration of Helsinki (1989) and with the
written informed consent of each subject. As in Chapter 3 the same eight healthy
male non smokers attended on three separate occasions at least 1 week apart. Each
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volunteer was studied at the same time of day and was fasting for at least 4 hours and
avoided alcohol and caffeine for 24 hours before each study. No medications or
vasoactive drugs were taken in the 7 days before the study.
Seventeen patients with stable NYHA grade II-IV heart failure, established for at
least 6 months on maximally tolerated ACE inhibitor therapy, were enrolled in the
study. The patients attended fasted before each study, and diuretics were withheld on
the morning of the study for patient comfort. Twelve patients initially attended at
9.00 a.m. on two occasions 1 week apart. ACE inhibitor therapy was withheld for
1 week before the second visit and recommenced after the second study. Nine
patients returned at least 4 weeks after recommencing their ACE inhibitor therapy
and underwent a repeat study. Two patients withdrew their consent because of
personal reasons, and one patient changed therapy before the third visit and was thus
excluded. Nine patients, including four patients who attended on the first three
occasions, were subsequently studied on a final occasion.
5.3.2 Measurements
Intra-arterial drug administration and FBF measurements were performed as
previously described [Webb 1995; Newby et al 1999b]. Heart rate and blood pressure
were measured non-invasively in the non-infused arm immediately after the FBF
measurements every 10 minutes throughout each study using a semi-automated,
sphygmomanometer (UA-731, A&D Engineering).
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5.3.3 Drugs
B9340 (molecular weight 1318.6) is a synthetic peptide antagonist of bradykinin that
differs from HOE-140 (icatibant; molecular weight 1304.6) by replacement of the <*-
(2-indanyl)glycine at position 7 of the molecule with a tetrahydroisoquiniline-3-
carboxylic acid moiety. When compared with HOE-140 in animal studies, B9340
retains similar potency of inhibition at the B2 receptor (pICso of 9.8 for both) but
produces more than a 100-fold greater inhibition at the Bi receptor (pICso of 6.0 and
8.1 for E1OE-140 and B9340, respectively) [Stewart et al 1997]. Pharmaceutical
grade B9340 (Clinalfa AG), HOE-140 (Clinalfa), substance P (Clinalfa), and
bradykinin (Clinalfa) were dissolved in 0.9% saline before infusion. All solutions
were freshly prepared on the day of study.
5.3.4 Protocol Design
Healthy Volunteer Study
After 30 minutes equilibration with saline infusion, intra-arterial placebo (0.9%
saline), B9340 at 4.5 nmol/min, or B9340 at 13.5 nmol/min was infused for
100 minutes on separate occasions in a randomised, ascending dose, double-blind
manner. Placebo or B9340 was coinfused with saline, with bradykinin at 30, 300, and
3000 pmol/min for 10 minutes at each dose, and, after 30 minutes saline infusion,
with substance P at 4, 8, and 16 pmol/min for 10 minutes at each dose. Throughout
the study, FBF was measured every 10 minutes, and the final FBF measurement
taken during saline infusion was defined as the baseline FBF.
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Patient Study
On each of the first three occasions, B9340 was infused intra-arterially at 0.45, 1.35,
4.5, and 13.5 nmol/min for 6 minutes at each dose. The two extra doses were
included to demonstrate dose response. Subsequently, on the final occasion in nine
patients, HOE-140 was infused intra-arterially at 0.45, 1.35, 4.5, and 13.5 nmol/min
for 6 minutes at each dose. This dose was chosen to match that of B9340 which has
similar potency at the B2 receptor. On each occasion, drug infusion was preceded by
a 30 minute saline infusion, and unblinded FBF measurements were made for the last
3 minutes ofeach infusion period.
5.3.5 Data Analysis and Statistics
Mean arterial pressure was defined as the diastolic blood pressure plus a third of the
pulse pressure. Plethysmographic data were extracted from the Chart data files, and
FBF was calculated for individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel 97, Microsoft). Recordings from the first 60 seconds
after wrist cuff inflation were not used because of the variability in blood flow that
this causes [Webb 1995], Usually the last five flow recordings in each 3 minute
measurement period were calculated and averaged for each arm. To reduce the
variability of the blood flow data, the ratio of flows in the two arms was calculated
for each time point; in effect using the non-infused arm as a contemporaneous control
[Petrie et al 2000]. The percentage change in FBF after drug administration was
calculated as follows:
100 x F(i)ri/F(ni)n - F(i)y/F(ni)y
F(i)v/F(ni)v %
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where F(i) and F(ni) represent measured blood flows in the infused and non-infused
arms, respectively, during periods of drug (d) and vehicle (v) administration [Webb
et al 1995].
Data are presented as mean ± SEM. On the basis of the responses, dose response
shifts were calculated for the ED300, the dose producing a 300% increase in basal
FBF. Comparisons between groups were made using 2-way ANOVA and, where




Mean age of the subjects was 25±5 years, and mean body mass index was 22±2
kg/rrr. B9340 was well tolerated without any adverse events. There were no
significant changes in FBF in the non-infused arm, heart rate, or mean arterial
pressure during the infusions (data on file). B9340 infusion alone caused no
significant change in infused FBF at either dose (at 4.5 nmol/min, 8±8%; at 13.5
nmol/min, 4±5%) compared with placebo (-7±7%: 2-way ANOVA, placebo versus
high dose, p=0.8).
During placebo infusion, both bradykinin and substance P caused dose-dependent
vasodilatation in the infused forearm (ANOVA, p<0.001 for both). At doses of
4.5 and 13.5 nmol/min, B9340 inhibited the vasodilatation produced by intra-arterial
bradykinin (2-way ANOVA, p<0.001 for both doses; Figure 5.1) and resulted in a
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5-fold and 30-fold increase in the ED300 of bradykinin respectively. B9340 infusion
had no effect on substance P-induced vasodilatation (Figure 5.1).
Figure 5.1 Percentage change in forearm blood flow during substance P (closed symbols) and
bradykinin (open symbols) infusion during coinfusion of placebo (circles), B9340 at 4.5 nmol/min
(squares), and B9340 at 13.5 nmol/min (triangles) in healthy volunteers. *p<0.001. 2-way ANOVA
with repeated measures.
Patient Study
Patient characteristics are shown in Table 5.1. Two patients reported an increase in
symptoms of breathlessness after withdrawal of their ACE inhibitor therapy for
1 week, which improved after recommencing therapy. During B9340 infusion, there
were no significant changes in heart rate, mean arterial pressure, or baseline FBF
between the 2 study days, although there was a trend for mean arterial pressure to be
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higher when withdrawn from ACE inhibitor therapy (99±4 mmHg versus
93±4 mmHg, paired /-test, p=0.08).
Visit 1 Visit 2 Visit 3 Visit 4
Number 12 9 9
Age (range), years 65 (51-78) 65 (52-78) 65(51-79)
Sex, maleifemale 10:2 7:2 9:0
NYHA grade, II:III:IV 4:6:2 2:6:1 5:4:0
IHD:DCM 9:3 ... 6:3 8:1
Medication
ACE inhibition 12 9 9
Aspirin 11 8 6
Diuretic 10 7 7
B-Blocker 3 2 2
Lipid-lowering therapy 6 5 5
Nitrate 5 4 3
Digoxin 5 4 2
Calcium antagonist 3 3 3
Amiodarone 2 2 2
Warfarin 1 1 3
EF, % 36±5 36±6 27±4
SF, % 14±3 15±3 10±4
LVEDD, mm 71±4 68±4 68±5
Heart rate, beats/min 60±4 55±4 55±4 67±4
MAP, mm Hg 93±4 99±4 108±8 91±5
Basal FBF, mL/100 mL per
min
Infused 2.8±0.3 2.7±0.3 J 2.8±0.3 2.9±0.4
Non-infused 2.6±0.2 3.5±0.5 2.6±0.3 2.6±0.3
Table 5.1 Patient Characteristics. Values are mean±SEM, mean (range), or number of patients.
DCM indicates dilated cardiomyopathy; EF, ejection fraction; FBF, forearm blood flow; IHD,
ischaemic heart disease; LVEDD, left ventricular end diastolic diameter; MAP, mean arterial
pressure; and SF, shortening fraction.
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B9340 caused a dose-dependent vasoconstriction in the infused forearm during
chronic ACE inhibition (ANOVA, p=0.01; Figure 5.2) that was abolished after
withdrawal of therapy (2-way ANOVA, ACE inhibition versus no ACE inhibition,
p<0.001). Moreover, B9340 again caused a dose-dependent vasoconstriction
(ANOVA, p<0.03) in the nine patients who returned for an additional visit at least
4 weeks after recommencing maintenance ACE inhibitor therapy. The change in FBF
was not significantly different between the first and third visits (2-way ANOVA,
p=NS), but it was again significantly different from the response after withdrawal of
ACE inhibitor therapy (2-way ANOVA, p<0.005). On the final occasion, intra¬
arterial infusion of HOE-140 had no significant effect on basal FBF during
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Figure 5.2 Percentage change in forearm blood flow with intrabrachial infusion of B9340 during ACE
inhibition (•, n=12), after withdrawal of ACE inhibition (o, n=12), and after reinstitution of therapy (■,
n=9) in patients with heart failure. Subsequent forearm blood flow response to intrabrachial HOE-140
infusion in patients with heart failure maintained on ACE inhibitor therapy is also shown (A, n=9). There
were no significant changes in forearm blood flow with B9340 in the absence of ACE inhibition or HOE-
140 in the presence ofACE inhibition. *p<0.01; +p<0.03. ANOVA with repeated measures.
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5.5 DISCUSSION
We have shown that B9340, a novel peptidic bradykinin receptor antagonist, causes a
dose-dependent inhibition of bradykinin mediated forearm vasodilatation without
influencing responses to substance P or affecting basal vascular tone. In addition, we
have shown for the first time that B9340 causes peripheral vasoconstriction in
patients with heart failure during the maintenance of chronic ACE inhibitor therapy.
We conclude that in patients with heart failure, endogenous bradykinin may
contribute to the vasodilatation produced by chronic ACE inhibition.
In healthy volunteers, we have shown that B9340 selectively inhibits vasodilatation
mediated by bradykinin but not substance P. Moreover, when B9340 is infused into
the forearm at doses sufficient to increase the ED300 of bradykinin 30-fold, it causes
no significant change in basal FBF. This indicates that bradykinin, unlike nitric
oxide, does not provide a major contribution to the regulation of basal vascular tone
in healthy humans. This is in keeping with the work of other groups who have shown
that intravenous administration of a bradykinin receptor antagonist does not affect
systemic haemodynamic parameters in healthy volunteers [Cockcroft et al 1994a].
The discovery and subsequent development of compounds to inhibit ACE arose from
research into bradykinin potentiating factor. This protein was found not only to
augment the effects of bradykinin on smooth muscle but also to inhibit ACE activity
[Ondetti et al 1971]. It was later realised that the enzymes responsible for bradykinin
degradation (kininase II) and angiotensin II generation (ACE) are the same protein.
Therefore, it is not surprising that some of the vascular effects of ACE inhibition are
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attributable to the action of bradykinin [Hornig et al 1997]. We have shown that in
healthy volunteers, ACE inhibition causes an increase in the flow associated
vasodilatation of reactive hyperaemia, an effect blocked by HOE-140. In sodium
depleted volunteers and patients with hypertension, Gainer et al [1998] have shown
that the acute hypotensive effects of captopril can be ameliorated by intravenous
administration of HOE-140. These studies, however, relate only to the acute effects
of ACE inhibition and may not be representative of the vascular effects during
chronic ACE inhibition.
The only previous study to assess directly the contribution of bradykinin to basal
vascular tone in heart failure showed an apparent, but non-significant,
vasoconstriction with intra-arterial HOE-140 in patients treated with enalapril [Davie
et al 1999]. The apparent disparity between our study and that by Davie et al [1999]
may reflect the differing pharmacological actions of HOE-140 and B9340. To
address this issue, we subsequently assessed the effects of HOE-140 in a limited
number of patients, including four subjects who had received B9340. We also found
no significant vasoconstrictor effects of HOE-140 in patients with chronic heart
failure maintained on ACE inhibitor therapy.
Des-Arg9-bradykinin, a selective Bi receptor agonist, is the product of kininase I
action on bradykinin [Lamontagne et al 1995]. Theoretically, if ACE (kininase II) is
inhibited, bradykinin will be preferentially metabolised to des-Arg9-bradykinin.
Indeed, there is a suggestion that potentiation of des-Arg9-bradykinin may, in part, be
responsible for some of the side effects of ACE inhibitor therapy, including angio-
oedema [Blais et al 1999]. It has been shown in dogs that infusion of des-Arg9-
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bradykinin causes resistance and conduit vessel dilatation [Su et al 2000]. In our
study, we have used a relatively non-selective bradykinin receptor antagonist, B9340,
which, although retaining a similar activity at the B2 receptor, has a 100-fold greater
affinity for the Bj receptor than HOE-140 [Stewart et al 1997], Moreover, Bi
receptor expression on vascular endothelium is upregulated in inflammatory
conditions [Marceau 1995] and atherosclerosis [Raidoo et al 1997], and there is now
evidence that inflammation plays an important role in heart failure, with elevated
plasma concentrations of circulating cytokines, such as tumor necrosis factor-a- and
interleukin IB [Kelly and Smith 1997]. Thus, the vasoconstrictor effects of B9340
may represent combined inhibition of the vascular actions of des-Arg9-bradykinin
and bradykinin at the Bi and B2 receptors. However, to date, the biological activity
and functional significance of des-Arg9-bradykinin and Bi receptor mediated effects
have not been assessed in humans.
This study has wide ranging implications for future work on ACE inhibition. If part
of the benefit of ACE inhibitor therapy is attributable to increases in endogenous
bradykinin and its metabolites, then even greater benefit might be obtained from
combined ACE and neutral endopeptidase (NEP) inhibition. Indeed, in vivo animal
[Raut et al 1999] and ex vivo human [Kokkonen et al 1999] studies have
demonstrated that the actions of bradykinin are augmented additionally by combined
ACE and NEP inhibition. Moreover, the recent IMPRESS trial [Rouleau et al 2000]
showed a significant benefit over lisinopril in the combined endpoint of death,
hospital stay, or discontinuation of study medication for worsening of heart failure
when patients with heart failure were treated for 24 weeks with omapatrilat, a
combined ACE and NEP inhibitor. However, combined vasopeptidase inhibitors like
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omapatrilat also augment other peptidic systems, such as the natriuretic peptides, and
it remains to be established whether bradykinin provides a greater contribution to the
maintenance of basal vascular tone in patients treated with these agents.
5.6 CONCLUSION
In conclusion, B9340 is a potent and specific inhibitor of bradykinin-induced
peripheral vasodilatation. Using B9340 at doses sufficient to increase the ED300 of
bradykinin by 30-fold, we have demonstrated that bradykinin contributes to the
maintenance of basal peripheral vascular tone in patients receiving chronic ACE
inhibitor therapy for heart failure. Since this work was performed a further study has
demonstrated that ACE inhibition augments bradykinin mediated vasodilatation and
endogenous tPA release only via the B2 receptor [Cruden et al 2005],
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CHAPTER 6
BRADYKININ CONTRIBUES TO THE SYSTEMIC HAEMODYNAMIC
EFFECT OF CHRONIC ANGIOTENSIN-CONVERTING ENZYME
INHIBITION IN PATIENTS WITH HEART FAILURE
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6.1 SUMMARY
Background - Bradykinin is an endogenous vasodilator that may contribute to the
systemic effects of ACE inhibitor therapy. Using B9340, a bradykinin receptor
antagonist, we determined the contribution of bradykinin to the systemic
haemodynamic effects of long-term ACE inhibition in patients with chronic heart
failure.
Methods and Results - Fourteen patients with heart failure received enalapril (10
mg twice daily) or losartan (50 mg twice daily) in a randomised double-blind
crossover trial. After 6 weeks treatment, patients underwent right heart
catheterisation and were randomised to an intravenous infusion of B9340 (2-20
pg/kg/min) or saline placebo. After B9340 infusion in patients treated with enalapril,
mean arterial pressure (+5.2 mmHg), systemic vascular resistance (+315
dynes-s/cm5), pulmonary arterial wedge pressure (-1.4 mm Elg), and mean
pulmonary arterial pressure (-1.3 mm Elg) were greater compared with losartan
(p<0.005, p<0.07, p<0.0001, and p<0.05 respectively) or placebo infusion (p<0.005
for all). There was a reduction in cardiac output after B9340 with enalapril compared
with placebo (p<0.001) but not losartan.
Conclusions - Bradykinin contributes to the systemic haemodynamic effects of long-
term ACE inhibition in patients with heart failure. This mechanism may explain the
apparent clinical differences between ACE inhibitors and angiotensin receptor
blockers in the treatment of heart failure.
98
6.2 INTRODUCTION
Activation of the renin-angiotensin-aldosterone system plays a key role in the
pathogenesis of chronic heart failure, leading to salt and water retention and
peripheral vasoconstriction. Inhibitors of ACE reduce peripheral vascular tone and
systemic arterial pressure [Powers et al 1982] and improve symptoms and survival
inpatients with chronic heart failure [The CONSENSUS Trial Study Group 1987].
Although previously attributed to a reduction in angiotensin mediated
vasoconstriction, recent data have indicated that the haemodynamic changes
associated with ACE inhibitor therapy may be caused, at least in part, by the
inhibition of bradykinin metabolism. The bradykinin metabolising properties ofACE
(kininase II) were first described in 1967 [Erdos and Yang 1967]. Indeed, ACE has
greater affinity for bradykinin than for angiotensin I [Jaspard et al 1993] and is the
principal enzyme responsible for the rapid turnover of bradykinin (plasma half-life
-15 seconds) [Bonner et al 1990], This rapid metabolism makes accurate
measurement of bradykinin difficult, although elevated plasma bradykinin
concentrations have been reported in the presence of ACE inhibition [Pellacani et al
1994], Bradykinin is a powerful endothelium-dependent vasodilator and, at a
functional level, inhibition of ACE potentiates the action of exogenous bradykinin in
the human forearm and coronary circulations [Benjamin et al 1989; Kuga et al 1997;
Witherow et al 2002], There are two principal kinin receptor subtypes in humans, Bi
and B2 [Stewart et al 1997]. The endothelial B2 receptor is constitutively expressed
and mediates the vasodilator and profibrinolytic effects of bradykinin [Cockcroft et
al 1994a; Brown et al 2000]. The vascular Bi receptor is normally expressed very
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weakly but is markedly upregulated in the presence of inflammation, cardiovascular
disease states [McLean et al 2000] and ACE inhibition [Marin-Castano et al 2002],
where it also mediates vasodilatation [Drummond and Cocks 1995]. The selective
kinin receptor antagonists, HOE-140 (icatibant) and B9340, are synthetic peptide
analogues of bradykinin with different inhibitory activities at the specific kinin
receptor subtypes. HOE-140 acts solely at the EL receptor, whereas B9340 blocks
kinin activity mediated via both Bi and B2 receptors [Stewart et al 1997], Several
investigators have reported that intravenous HOE-140 attenuates the vasodepressor
response associated with acute ACE inhibition, both in healthy volunteers and in
hypertensive patients [Gainer et al 1998; Squire et al 2000], In contrast, B9340, but
not HOE-140, induced vasoconstriction in the forearm circulation of patients with
heart failure treated with chronic ACE inhibitor therapy [Davie et al 1999; Witherow
et al 2001]. Besides implicating bradykinin in the haemodynamic changes associated
with ACE inhibition, these data raise the possibility of a role for the Bi receptor in
patients with chronic heart failure [Witherow et al 2001]. The aims of the present
study were to demonstrate that the kinin receptor antagonist, B9340, inhibits
bradykinin activity in the systemic circulation and to determine whether endogenous
bradykinin contributes to the haemodynamic effects of long-term ACE inhibition in
patients with chronic symptomatic heart failure.
6.3 METHODS
6.3.1 Study Subjects
The protocols were performed with the approval of the Local Research Ehics
Committee and in accordance with the Declaration of Helsinki (1989). Written
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informed consent was obtained from each subject. Six healthy, male non smokers
attended fasted at 8.00 a.m. on two occasions at least 1 week apart. Volunteers
avoided alcohol and caffeine for 24 hours before each study and received no
medications or vasoactive substance in the preceding 7 days. Fourteen patients with
stable NYHA class II—III chronic heart failure and objective evidence of left
ventricular impairment (left ventricular ejection fraction <40%, shortening fraction
<20%, or left ventricular end diastolic diameter <5.5 cm) were enrolled into the
study. Patients were included only if they had been established on maximally
tolerated ACE inhibitor therapy for at least 6 months. Patients were excluded if they
had significant valvular heart disease, renal or hepatic failure, or had previous
malignant ventricular arrhythmias. After initial screening, patients received enalapril
10 mg [The CONSENSUS Trial Study Group 1987] or losartan 50 mg [Pitt et al
2000], both twice daily, in place of their usual ACE inhibitor in a randomised
double-blind crossover trial. There was no placebo limb of the trial as it was felt that
it would be unethical to have patients with heart failure untreated by some form of
angiotensin blockade for such a long period.
After 6 weeks of each treatment, subjects attended fasted at 8.00 a.m. and underwent
right heart catheterisation. On the morning of each visit, oral study medication was
administered at 7.00 a.m. to achieve peak plasma concentrations of the active
metabolites, enalaprilat or E-3174, respectively, during B9340 or placebo infusion





Intra-arterial drug administration and FBF measurements were performed using
venous occlusion plethysmography as previously described [Witherow et al 2001],
After each FBF measurement, heart rate and blood pressure were determined non-
invasively in the non-infused arm using a semi-automated, sphygmomanometer (UA-
731; A&D Engineering, Milpitas, Calif).
Patient Study
A 9-French venous sheath was inserted aseptically under local anaesthesia via the
right femoral vein. Under fluoroscopic screening, a continuous CO thermodilution
Swan-Ganz catheter (Edwards Lifesciences, Irvine, Calif) was positioned in the
pulmonary arterial tree. Pulmonary arterial pressure, pulmonary arterial wedge
pressure, and central venous pressure were recorded using a Hewlett Packard
monitor (U78339A; Hewlett Packard, Andover, Mass). Continuous cardiac output
was recorded using a Vigilance monitor (Edwards Lifesciences, Irvine, Calif). Heart
rate and blood pressure were measured non-invasively using a semi-automated
sphygmomanometer (U78339A; Hewlett Packard, Andover, Mass).
6.3.3 Drugs
B9340 (molecular weight 1318.6) is a synthetic peptide antagonist of bradykinin
with potent inhibitory activity at both the Bi and B2 receptors (pIC50 in vitro of 8.1
and 9.8, respectively) [Stewart et al 1997], The doses of B9340 and bradykinin were
chosen after the results of dose ranging studies performed in the forearm circulation
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of healthy volunteers [Witherow et al 2003]. Pharmaceutical grade B9340 and
bradykinin were supplied by Clinalfa AG (La'ufelfmgen, Switzerland) and dissolved
in saline on the day of study.
6.3.4 Protocol Design:
Healthy Volunteer Study
After 30 minutes equilibration with saline infusion, bradykinin was infused via the
brachial artery of the non-dominant arm at 300 pmol/min for 120 minutes. B9340 or
saline placebo was infused intravenously in the contralateral arm at 2, 6, and 20
pg/kg/min for 12 minutes at each dose with 12 minutes separating each dose.
Forearm blood flow was measured at 6 minute intervals throughout each study.
Patient Study
After a 30 minute infusion of 50 mL saline, patients received an intravenous infusion
of B9340 at 2, 6, and 20 pg/kg/min for 15 minutes at each dose or saline placebo (75
mL) in a randomised, double-blind manner. The randomisation was weighted such
that 10 patients on enalapril received B9340, 10 patients on losartan received B9340,
and six patients on either enalapril or losartan received placebo. Haemodynamic
measurements were recorded at -40, -30, -10, 0 (baseline), 7, 15, 22, 30, 37, 45, 60,
75, 90, and 105 minutes during each study. Venous blood was collected at 0




Blood samples were collected on ice, centrifuged immediately, and the resulting
supernatant stored at -70°C until assayed. Plasma ACE activity was determined using
colorimetric spectrophotometry (SIGMA Diagnostics, St Louis, Mo) (Holmquist et al
1979). After extraction using Bond Elut columns (Varian; Harbor City, Calif),
plasma angiotensin II (Diasorin, Stillwater, Minn) concentrations were determined
by radioimmunoassay [Morton and Webb 1985].
6.3.6 Data Analysis and Statistics
Data are expressed as mean ± standard error of the mean. Mean arterial pressure was
defined as diastolic pressure plus a third of the pulse pressure. Forearm blood flows
were calculated from plethysmographic data as described previously [Witherow et al
2001. In patient studies, haemodynamic parameters were assessed over time as
absolute change from baseline (0 minutes) using 1-way ANOVA with repeated
measures. Comparisons between treatment groups were made using 2-way ANOVA
for which the within subject variables were drug and time. Plasma neurohormone
concentrations were compared at baseline using an unpaired /-test. Statistical
significance was taken at the 5% level.
6.4 RESULTS
Healthy Volunteer Study
Bradykinin caused a sustained increase in FBF during placebo coinfusion (p<0.0001;
Figure 6.1). Systemic infusion of B9340 inhibited bradykinin mediated





Figure 6.1 Effect of systemic B9340 (2 to 20 jig/kg per minute; closed circles) and placebo infusion
(open circles) on bradykinin mediated forearm vasodilatation in healthy volunteers, *p<0.001.
Patient Study
Fourteen patients participated in the haemodynamic study. After the first visit, one
patient withdrew because of worsening heart failure unrelated to treatment and was
replaced. There were no significant differences in patient characteristics or baseline









Age in years (range) 62 (45-75) 63 (45-78) 66(60-73)
Gender (male/female) 8/2 9/1 5/1
Diagnosis (IHD/DCM) 9/1 8/2 5/1
NYHA class (II/III) 8/2 6/4 3/3
Ejection fraction (%) 28 (3) 28 (3) 31(2)
Body mass index 26(1) 26(1) 25 (2)
Concomitant
medications
Aspirin 8 8 6
Diuretic 9 8 5
Beta-blocker 7 6 3
Statin 7 6 5
Nitrate 3 3 3
Digoxin 2 1 3
Calcium antagonist 1 2 1
Spironolactone 0 1 1
Baseline hemodynamics
Heart rate (beats/min) 62 (3) 62(4) 61(3)
MAP (mm Hg) 81 (4) 83 (4) 83 (3)
SVR (dynes.s/cm5) 1228 (116) 1194(110) 1443 (80)
Cardiac output (L/min) 5.4 (0.4) 5.6 (0.5) 4.7 (0.2)
CVP (mm Hg) 1(1) 1(1) 1(1)
MPAP (mm Hg) 15(2) 18(2) 15(2)
PAWP (mm Hg) 5(1) 9(2) 7(1)
Plasma Neurohormones
Plasma ACE activity and plasma angiotensin II concentrations at baseline on the
morning of haemodynamic studies were significantly lower in patients treated with
enalapril compared with losartan respectively (Figure 6.2). There were no significant
changes in plasma ACE activity or angiotensin II concentrations during or after
B9340 or placebo infusion.
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p<0.0001 p<0.005
ENALAPRIL LOSARTAN ENALAPRIL LOSARTAN
Figure 6.2 Baseline plasma ACE activity (n=14) and angiotensin II (n=13) concentrations in
patients with heart failure after 6 weeks of therapy with enalapril (open bar) or losartan (solid bar).
Mean Arterial Pressure and Heart Rate
There were no significant changes in heart rate or mean arterial pressure during
placebo infusion or after losartan therapy. Mean arterial pressure increased after
administration ofB9340 in patients treated with enalapril (p<0.005; Figure 6.3),
although there was no significant change in heart rate. This pressor effect was greater
in patients treated with enalapril than those given losartan therapy or placebo
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■ Enalapril + B9340 infusion O Losartan + B9340 infusion X Placebo infusion
Figure 6.3 Changes in (a) mean arterial pressure (MAP), (b) systemic vascular resistance (SVR), and
(c) cardiac output (CO) after intravenous infusion of saline placebo (crosses) or B9340 (2 to 20 pg/kg
per minute) in patients with chronic heart failure treated with enalapril (black squares) or losartan
(white circles).
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There were no significant changes in cardiac output or systemic vascular resistance
during placebo infusion or after losartan therapy. In patients treated with enalapril
receiving B9340, there was a trend toward an increase in systemic vascular resistance
(p<0.08) but no change in CO.
Central Pressures
Central venous pressure, pulmonary arterial wedge pressure, and mean pulmonary
arterial pressure all decreased significantly over time during placebo infusion
(p<0.05 for all; Figure 6.3). Compared with losartan therapy or placebo infusion,
B9340 attenuated the decrease in pulmonary arterial wedge pressure (p<0.0001 for
both) and mean pulmonary arterial pressure (p<0.05 and p<.005, respectively) in
patients treated with enalapril (Figure 6.3). There were no significant differences in
the reductions of central venous pressure between treatment groups (Figure 6.3).
Adverse Events
There were no major drug related adverse events reported during healthy volunteer
or patient studies. Three healthy volunteers and one patient reported mild self-
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Figure 6.4 Changes in (a) pulmonary arterial wedge pressure (PAWP), (b) mean pulmonary arterial
pressure (MPAP), and (c) central venous pressure (CVP) after intravenous infusion of saline placebo
(crosses) or B9340 (2 to 20 pg/kg per minute) in patients with chronic heart failure treated with





We have demonstrated that intravenous B9340, a selective peptidic antagonist of
bradykinin receptors, causes systemic inhibition of bradykinin mediated
vasodilatation in a dose-dependent manner. This bradykinin receptor antagonist has a
significant pressor effect in patients with chronic heart failure maintained on long-
term ACE inhibitor but not angiotensin receptor blocker therapy. These findings
provide convincing evidence that bradykinin contributes to the hypotensive effects of
chronic ACE inhibitor therapy in patients with heart failure. We have previously
shown that B9340 causes vasoconstriction in the forearm circulation in patients with
heart failure treated with long-term ACE inhibitor therapy [Witherow et al 2001],
The results of the present study confirm that these effects are important in the
systemic circulation. This is consistent with published data demonstrating that the
bradykinin receptor antagonist, HOE-140, attenuates the acute vasodepressor
response to ACE inhibition. Gainer et al [1998] demonstrated that in salt-deplete
healthy volunteers and hypertensive subjects, a systemic infusion of HOE-140
attenuated the hypotensive response to a single dose of captopril. The reduction in
blood pressure observed after coadministration of HOE-140 and captopril was
similar to that seen with the angiotensin receptor blocker, losartan [Gainer et al
1998], As the authors point out, previous studies have demonstrated that the peak
hypotensive responses to captopril and losartan occur 1 and 4 hours, respectively,
after drug administration [Gainer et al 1998]. It has been suggested that these
differences could account for the observed differences in the blood pressure
response. To overcome this potential methodological difficulty, we chose to compare
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the ACE inhibitor, enalapril, at a dose previously shown to reduce mortality in
patients with heart failure [The CONSENSUS Trial Study Group 1987] with the
angiotensin receptor antagonist, losartan, administered at the maximum daily dose.
Both these agents have long-acting active metabolites, enalaprilat and E-3174,
respectively, achieving peak plasma concentrations 3 to 4 hours after ingestion that
coincided with systemic intravenous administration of B9340 or placebo [Abrams et
al 1984; Ohtawa et al 1993], It should also be recognised that we have assessed the
effects of kinin receptor blockade in patients maintained on long-term ACE inhibitor
therapy rather than the acute effects of a single oral dose. Moreover, patients with
heart failure maintained on chronic ACE inhibitor therapy may upregulate vascular
Bi kinin receptor expression [Witherow et al 2001] and we therefore used a
combined Bi and Bi receptor antagonist to characterise more precisely the role of
bradykinin.
It has been argued [Schiffrin 2002] that angiotensin receptor blockade might
potentially be more effective at blocking the detrimental effects of angiotensin II
than ACE inhibition because in a substantial proportion of patients treated with
chronic ACE inhibition, plasma angiotensin II concentrations increase over time
returning toward pretreatment values [MacFadyen et al 1999], This "ACE escape" is
thought to be caused by angiotensin II formation by non ACE dependent pathways
and may be associated with a poorer prognosis [Petrie et al 2001], However, clinical
evidence that angiotensin receptor blockers have superior efficacy to ACE inhibitor
therapy has proved elusive. In contrast, recent trials have confirmed that the
therapeutic benefits ofACE inhibitors and angiotensin receptor blockers are additive:
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combination therapy improving symptoms and cardiovascular mortality in patients
with heart failure when compared with ACE inhibition alone [Cohn and Tognoni
2001; McMurray et al 2003]. Our findings may help to explain the additive benefits
of combined ACE inhibition and angiotensin receptor blockade. Large scale clinical
trials have demonstrated that ACE inhibitors not only improve survival but reduce
the incidence ofmyocardial ischaemia [Flather et al 2000], This may be explained, in
part, by the observation that ACE inhibition improves the fibrinolytic balance in
patients with heart failure and ischaemic heart disease [Wright et al 1994].
Bradykinin is not only a potent vasodilator but is intimately involved with the
coagulation and fibrinolytic cascades. Indeed, it is a powerful mediator of
endogenous fibrinolysis through the release of endothelium-derived t-PA [Brown et
al 2000; Witherow et al 2002; Pretorius et al 2003]. In patients with heart failure,
chronic ACE inhibition markedly augments local bradykinin mediated release of t-
PA [Witherow et al 2002]. Thus, potentiation of the other vascular actions of
bradykinin may also contribute to the clinical benefits ofACE inhibitor therapy.
In patients treated with losartan, there was a small but significant increase in mean
arterial pressure and systemic vascular resistance after B9340 infusion compared
with placebo. This may have reflected the significant protein load associated with
B9340 infusion and a protein based placebo, such as albumin, may have been a more
appropriate control. There are data indicating that bradykinin may contribute to the
vascular effects of angiotensin receptor blockers. In transgenic mice overexpressing
the AT2 receptor, angiotensin II causes vasodilatation that is attenuated by HOE-140
[Tsutsumi et al 1999] and in human, HOE-140 inhibits the improvement in flow
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mediated vasodilatation associated with the angiotensin receptor blocker, candesartan
[Hornig et al 2003], Finally, the findings are consistent with the possibility that
bradykinin also contributes to the maintenance of blood pressure and vascular tone in
patients with heart failure independently ofACE.
In summary, we have shown that in patients with chronic heart failure, systemic
infusion of the combined kinin receptor antagonist, B9340, attenuates the
vasodepressor effects associated with long-term enalapril therapy when compared
with treatment with the angiotensin receptor blocker, losartan.
6.6 CONCLUSION
We conclude that in patients with chronic symptomatic heart failure, bradykinin
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7.1 BRADYKININ MEDIATED STIMULATION OF THE
ENDOTHELIUM
Stimulation of the forearm vascular bed with bradykinin is associated with a
selective and reproducible vasodilatation and release of t-PA at intrabrachial doses of
30 nmol/min or higher. This endothelial cell stimulation can be inhibited by B9340 a
bradykinin receptor antagonist with high affinity for the Bi receptor. B9340 failed to
inhibit substance P mediated dilation and t-PA release thus confirming that
bradykinin stimulates the endothelium via a specific receptor rather than a
generalised mechanism. Furthermore bradykinin mediated forearm vasodilatation
and endothelial t-PA release was enhanced by the presence but not the absence of
ACE inhibition in patients with heart failure.
7.1.1 Bradykinin Mediated Tissue PlasminogenActivator Release
The ability of intra-arterial bradykinin to release t-PA from the endothelium can be
reproduced by other stimulants. Substance P can also produce rapid mobilisation of t-
PA from endothelial storage pools and is slightly more potent than bradykinin, and
desmopressin can also stimulate endothelial t-PA release [Newby et al 2000].
However not all endothelial stimulants are the same, as no discernable rise in t-PA
was seen after acetylcholine infusion despite producing vasodilatation [Brown et al
2000]. The potent vasoconstrictor angiotensin II did not produce any acute change in
plasma t-PA or PAI-1 levels [Labinjoh et al 2000], despite drug levels that produced
both local and systemic vasoconstrictor effects. Also increasing blood flow per se
does not release t-PA from the endothelium, as the endothelium independent
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vasodilator sodium nitroprusside did not produce any rise in t-PA or PAI-1 levels
despite producing marked vasodilatation [Newby et al 1997]. Thus it would seem
that intravascular t-PA release is specific to a few agonists acting on specific
receptors on the endothelium. It is of note however that kinin mediated endothelial t-
PA release can be increased by inflammation without a significant increase in blood
flow [Chia et al, 2003a].
The ability of the endothelium to produce enormous amounts of t-PA has been
shown in Chapter 4. At an infusion rate of 300 pmol/min of bradykinin, the maximal
local forearm concentrations of active t-PA (99 IU/ml) approached those observed
during systemic thrombolysis during acute myocardial infarction (100 to 1,000
IU/ml) (Koster). Moreover, it also underscores the ability of the endothelium to
release t-PA quickly, up to 4.5 pg or 16,000 IU/min from the infused forearm at 300
pmol/min of bradykinin. This ability to release t-PA seems to be sustainable at least
for 2 hours [Newby et al 1997],
7.1.2 Plasminogen Activator Inhibitor
It is also of note that despite the potent stimulation of t-PA release by substance P
and bradykinin there was no discernible acute release of PAI-1 from the
endothelium. Plasminogen activator inhibitor 1 is also produced in the endothelium
but does not seem to have the same ability to be rapidly mobilised despite its role in
deactivating t-PA by binding it in a t-PA/PAI-1 complex. Similarly in the human
coronary circulation, bradykinin stimulates endothelial release of t-PA without
affecting plasma concentrations of PAI-1 [Minai et al 2001], This seeming disparity
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between t-PA and PAI-1 would be advantageous when endothelium becomes
damaged, as the damaged area is procoagulant and the subsequent limitation of blood
clot propagation requires a rapid response from the endothelium to avoid ischaemia
in the distal bed.
7.2 ANGIOTENSIN-CONVERTING ENZYME INHIBITION AND TISSUE
PLASMINOGEN ACTIVATOR
The clinical and therapeutic benefits of inhibition of angiotensin-converting enzyme
has lead to the widespread use of ACE inhibitor therapy to treat a variety of
cardiovascular disorders including hypertension, myocardial infarction, vascular
disease and left ventricular dysfunction. Treatment with ACE inhibition tends to
produce vasodilatation and subsequent lowering of blood pressure in humans and
some of the haemodynamic effects may be due in part to enhanced bradykinin
activity in the vasculature. In addition to the haemodynamic effects, there is evidence
that bradykinin contributes to the increase in constitutive t-PA release associated
with ACE inhibitor therapy by a B2 receptor mechanism. In the forearm circulation of
healthy smokers, intra-arterial enalaprilat increased net basal t-PA release and this
effect was blocked by pre-treatment with HOE-140 [Pretorius et al 2003],
In this thesis, we confirmed earlier findings in healthy volunteers that bradykinin
stimulated t-PA release is augmented by treatment with ACE inhibition, [Labinjoh et
al 2001], However, it is of note that the amount of t-PA released by patients with
heart failure treated with chronic ACE inhibitor therapy in this study, was much
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greater than that of healthy volunteers treated with ACE inhibition in the study by
Labinjoh et al [2001], At a bradykinin infusion rate of 300 pmol/min, the t-PA
antigen concentration in infused arm was 11.7+1.7 ng/ml in healthy volunteers and
33.9+1.7 ng/ml in patients despite similar baseline levels of t-PA antigen. The more
accurate measure of t-PA production, the net t-PA release across the forearm
vascular bed shows that the ability of the patients with heart failure to release t-PA is
also greater (259.8+22 ng/lOOml/min) than healthy volunteers (90+22.9
ng/lOOml/min) when stimulated by 300 pmol/min of intrabrachial bradykinin. This
difference could be accounted for by the difference in age and size of the patients
compared to the volunteers, however if t-PA activity is compared between the two
different groups it can be shown that not only do the heart failure patients treated
with ACE inhibition have much higher basal levels of t-PA activity but also a far
greater ability to rapidly produce active t-PA. Interestingly when ACE inhibition is
withdrawn, the ability of the patients with heart failure to release t-PA is reduced
when compared to the healthy volunteers, demonstrating the endothelial dysfunction
that occurs in patients with heart failure. Thus it would seem that the benefits ofACE
inhibition on endothelial t-PA release are greater in disease than in health. This may
be part of the explanation why greater benefits of ACE inhibitor therapy are seen in
more severe disease such as heart failure with severe left ventricular impairment
[The CONSENSUS Trial Study Group 1987] compared to high risk vascular disease
without left ventricular impairment [The HOPE Study Investigators 2000].
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7.3 ANGIOTENSIN-CONVERTING ENZYME INHIBITION AND
PLASMINOGEN ACTIVATOR INHIBITOR
In Chapter 4 it was also seen that basal PAI-1 levels were greater in the absence than
in the presence of ACE inhibitor therapy. This confirms previous data that ACE
inhibition lowers levels ofPAI-1 in patients with heart failure. [Vaughan et al 1995b;
Goodfield et al 1999], As the basal level of PAI-1 is lower there will be less PAI-1 to
bind and inactivate t-PA showing that ACE inhibition not only increases the amount
of t-PA released in response to bradykinin stimulation but also reduces the amount of
inactivation of t-PA.
7.4 BRADYKININ MEDIATED VASODILATATION
Intravenous administration of bradykinin results in arteriolar vasodilatation and a
rapidly reversible fall in blood pressure and peripheral vascular resistance [Bonner et
al 1990], and intra-arterial administration produces local vasodilatation [Labinjoh et
al 2001], In this thesis, it has been demonstrated that endogenous bradykinin does
not appear to contribute to the maintenance of peripheral vascular tone in healthy
volunteers or in patients with heart failure which confirms the work of others who
have shown that local, intra-arterial infusion of E1OE-140 has no effect on resting
blood flow [Elornig et al 1997; Davie et al 1999], and that intravenous administration
of HOE-140 has no effect on systemic blood pressure [Gainer et al 1998]. We have
also shown that in the human peripheral circulation, exogenous bradykinin causes a
dose-dependent increase in blood flow through an endothelium and bradykinin B2
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receptor dependent mechanism. As has been demonstrated by previous authors,
intrabrachial bradykinin administration appears to be well tolerated, with only minor
discomfort and mild oedema at high doses. (Cockroft et al 1994a; Brown et al 2000;
Labinjoh et al 2001).
7.5 HAEMODYNAMIC EFFECTS OF ACE INHIBITION AND
ANGIOTENSIN RECEPTOR BLOCKADE
As has been mentioned previously, angiotensin-converting enzyme's dual ability of
activating angiotensin I and inactivating bradykinin has led to the extensive
investigation of the enzyme and subsequent use of converting enzyme inhibitors and
angiotensin II receptor blockers in the treatment of cardiovascular disease. It has
been previously demonstrated that some of the acute effects of ACE inhibition on
blood pressure are due to bradykinin. Gainer et al [1998] reported that a systemic
infusion of HOE-140 attenuates the systemic response to a single oral dose of
captopril. The reduction in blood pressure observed following coadministration of
HOE-140 and captopril was similar to that seen with the angiotensin receptor blocker
losartan. In the Chapters 5 and 6, it has been shown that infusion of intra-arterial and
intravenous B9340 produces vasoconstriction in patients with heart failure treated
with chronic ACE inhibition but not in the absence of ACE inhibition. This strongly
suggests that ACE inhibition mediates some of its vasodilator effects via bradykinin.
We have also shown for the first time that ACE inhibition augments bradykinin-
induced vasodilatation in patients with heart failure, although it has been previously
demonstrated in healthy volunteers (Benjamin et al 1989; Labinjoh et al 2001).
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In Chapter 5, vasoconstriction in the ACE inhibitor treated group of heart failure
patients was mediated by B9340 and not HOE-140. From this it can be assumed that
some of the vasodilatation of chronic ACE inhibition must be Bi receptor mediated.
Stimulation of the Bi receptor with intra-arterial des-Arg-bradykinin in coronary
arteries in dogs has been shown to produce vasodilatation [Su et al 2000], although
the mechanism of the vasodilatation needs further elucidation. It has also been
reported that having certain polymorphisms of the Bi receptor gene have been shown
to increase cardiovascular risk in hypertensive patients [Dhamrait et al 2003]. Bi
receptor upregulation has been shown in vitro to be rapidly induced by inflammation
[Sardi et al 1998; Sardi et al 1999] in the form of bacterial lippopolysaccharide and
interleukin 1(3. Patients with heart failure also have increased levels of inflammatory
markers so this may explain why B9340 and not HOE-140 produced a local
vasoconstriction in this study.
7.6 ANGIOTENSIN RECEPTOR BLOCKADE AND BRADYKININ
In Chapter 6 we confirmed that our findings in the peripheral circulation also held
true in the systemic circulation. We initially demonstrated the safety of intravenous
B9340 in healthy volunteers and showed that it inhibited local exogenous bradykinin.
In patients with heart failure we were able to directly compare the systemic
bradykinin mediated effects of enalapril with losartan. It has previously been
postulated that by blocking the angiotensin II type-1 (ATi) receptor there would be a
greater bioavailability of angiotensin II to stimulate the angiotensin type-II (AT2)
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receptor leading to vasodilatation and that some of this vasodilatation is mediated by
bradykinin [Gohlke et al 1998]. Previous authors have also shown that HOE-140 can
inhibit the improvement seen in flow-mediated dilatation in healthy volunteers
treated with candesartan [Hornig et al 2003] and more recently elevated bradykinin
plasma levels have been found in patients with hypertension treated with losartan
[Campbell et al 2005].
In Chapter 6 our study showed there was a difference between the effects of placebo
and B9340 on systemic haemodynamics in the losartan treated patients. In the
losartan treated group of patients there was a non-significant rise in SVR during
B9340 infusion, but when this change in SVR was compared to placebo infusion it
was different as placebo infusion tended to produce a reduction in SVR. This
difference may be attributed to the significant protein load of the B9340 infusion,
however it may be that losartan may have systemic vasomotor effects mediated
through bradykinin in this group of patients.
7.7 FUTURE DIRECTIONS
Further investigation of the role of bradykinin in the regulation of vascular tone and
endogenous fibrinolysis should involve direct investigation of the bradykinin Bi
receptor, in both health and disease states. Further work should also concentrate on
elucidating the role of the other enzymes that degrade bradykinin namely NEP and
carboxypeptidase U also known as thrombin activatable fibrinolysis inhibitor
(TAFI). The biological activity of bradykinin degradation products, especially
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bradykinin 1-5, in the human vasculature should be addressed and finally, future
work should address whether the effects of bradykinin on endogenous fibrinolysis
also hold true in the human coronary circulation.
7.7.1 The Bradykinin Bi Receptor
Stimulation of the bradykinin Bi receptor produces vasodilatation in both
conductance and resistance vessels in dogs [Su et al 2000], and in the rodent kidney,
heart, and vasculature, B i receptor stimulation plays a role in the hypotensive effect
of ACE inhibitor therapy [Marin Castano et al 2002], Angiotensin-converting
enzyme inhibitors themselves may also be able to induce expression of the Bi
receptor by a mechanism dependent on direct stimulation of the Bi receptor itself
[Marin Castano et al 2002]. Induction of the Bi receptor can be rapidly produced by
cytokines, and also by ischaemia, atherosclerosis (Marceau et al 1998, McLean et al
2000] and acute myocardial infarction [Tschope et al 2000], During these conditions,
vasodilatation of the affected vascular bed would prove advantageous to help
improve ischaemia. The induction and activation of the Bi receptor, as a mediator of
vasodilatation may be one of the protective mechanisms initiated during such
conditions and this mechanism may be enhanced by ACE inhibition. Further study of
the Bi receptor in humans is required to ascertain whether Bi kinin receptor
stimulation results in vasodilatation and t-PA release and Bi receptor antagonism
causes vasoconstriction in patients with heart failure but not healthy volunteers.
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7.7.2 Vasopeptidase Inhibition.
As we have shown, bradykinin has beneficial effects on the vasculature including
vasodilatation and enhanced fibrinolysis. These benefits are enhanced by blockade of
angiotensin-converting enzyme. Increasing the bioavailability of bradykinin further
may be achieved by also blocking the enzyme NEP 24.11 also called neprolysin.
Neutral endopeptidase leaves bradykinin in a similar manner to ACE, releasing the
C-terminal dipeptide of bradykinin. Vasopeptidase inhibition refers to single
molecules that block both enzymes simultaneously e.g. omapatrilat. The
OVERTURE study assigned 5,770 patients with NYHA class II-IV heart failure to
treatment with either enalapril (10 mg twice daily) or omapatrilat (40 mg once daily)
for a mean of 14.6 months [Packer et al 2002)]. The primary endpoint of combined
risk of death or hospitalisation for heart failure requiring intravenous treatment was
not different for the two treatment groups, although analysis of secondary outcomes
showed the omapatrilat group had a 9% lower risk of cardiovascular death or
hospitalisation (p<0.024) and a 6% lower risk of death (p<0.34). Post-hoc analysis
showed an 11% lower risk for hospitalisation for heart failure in patients treated with
omapatrilat (p<0.012). Although this study did not show superiority in the primary
endpoint, there was reduction in cardiovascular mortality that may be due to the
beneficial effects of vasopeptidase inhibition on endogenous fibrinolysis. Further
studies of vasopeptidase inhibition are required to ascertain whether Bi and B2 kinin
receptor agonism and antagonism is potentiated by vasopeptidase inhibition.
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7.7.3 Thrombin Activatable Fibrinolysis Inhibitor
Thrombin activatable fibrinolysis inhibitor is a latent plasma procarboxypeptidase
also known as carboxypeptidase R, carboxypeptidase U, and procarboxypeptidase B
[Campbell and Okada 1989; Hendriks et al 1989; Eaton et al 1991], Thrombin
activatable fibrinolysis inhibitor is now recognised as the second physiological
substrate activated by the thrombin/thrombomodulin complex, the other being
protein C. It is important for dampening fibrinolysis by removal of plasmin-exposed
lysines on partially digested fibrin clots thereby restricting t-PA binding and further
activation of plasminogen [Bajzar et al 1995; Redlitz et al 1995]. Thus, activated
protein C (aPC) and TAFIa may play complementary roles in haemostasis, with aPC
dampening the clotting cascade and preventing excessive thrombin generation, while
TAFIa serves to protect the clot already formed at the site of injury. As well as
restricting t-PA activity, TAFI can also inactivate kinins by removing the C-terminal
arginine. Cleavage studies have shown that TAFIa is in fact 10-fold more efficient
than carboxypeptidase N (kininase I) in hydrolysing bradykinin in vitro to des-Arg-
bradykinin [Myles et al 2003], By inactivating bradykinin it further reduces the t-PA
activity by reducing t-PA release from the endothelium. Several TAFI inhibitors are
currently under development and may lead to potentially novel and important
therapies in the treatment and prevention of coronary artery disease. [Chang et al
2000; Suzuki K et al 2004], Further study is required to assess the affects of TAFI
inhibition on bradykinin mediated vasodilatation and t-PA release.
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7.7.4 Bradykinin 1-5
Inactivation of bradykinin can result in the creation of several fragments which were
originally thought to be inactive. Angiotensin-converting enzyme is able to cleave
bradykinin at two sites, resulting in bradykinin 1-5 (RPPGF or thrombostatin) or
bradykinin 1-7. Bradykinin 1-5 has recently been shown to be the stable metabolite
in plasma [Murphey et al 2000] and can be measured by liquid chromatography
tandem mass spectrometry with electrospray ionisation [Murphey et al 2001].
Thrombostatin is an inhibitor of a-thrombin induced platelet activation and an
inhibitor of both y- and a-thrombin induced platelet aggregation and secretion
without inhibiting adenosine diphosphate or collagen induced platelet activation
[Hassan et al 1999], Thrombostatin does not inhibit thrombin binding to platelets and
is as effective as aspirin in preventing electrolytic injury-induced left circumflex
coronary artery thrombosis in dogs with combined thrombostatin and aspirin therapy
resulting in a greater antithrombotic effect than aspirin alone [Hassan et al 1999]. In
an ex vivo model of balloon angioplasty injury to the vessel wall, thrombostatin was
as effective as aspirin in preventing platelet adherence to the vessel wall and fibrin
formation [Prieto et al 2002], Although thrombostatin has clear antithrombotic
effects in animals, further studies are required to ascertain whether thrombostatin has
a role in endogenous fibrinolysis in the human vasculature.
7.7.5 Coronary Circulation
Bradykinin is known to regulate resting and flow-mediated epicardial tone. Infusion
of the B2 receptor antagonist icatibant into left main coronary arteries of patients with
significant coronary stenosis resulted in reduction in arterial luminal area, increased
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coronary vascular resistance, and decreased coronary blood flow (Groves et al.
1995). Patients with significant coronary artery disease demonstrate reduced
coronary artery vasodilation in response to BK (Kuga et al. 1995). In patients with
mild atherosclerosis or its risk factors, BK-induced coronary artery vasomotion was
near normal; however, BK-induced vasodilation was depressed following epicardial
stress induced with pacing (Prasad et al. 2000). A study comparing expression of
kinin receptors on normal and atheromatous blood vessels most strikingly revealed
increased Bi receptor expression on multiple cells within the atheromatous vessels
(Raidoo et al. 1997). The cells showing increased Bi receptor immunostaining
included endothelial cells, foamy macrophages, inflammatory cells, proliferating
fibroblasts, and smooth muscle cells.
Different vascular beds are able to release different amounts of t-PA, such that the
upper limbs release four times the amount of the lower limbs [Keber 1988], The
ability of the coronary circulation to acutely release t-PA has been demonstrated by
stimulation with intracoronary infusion of substance P [Newby et al 2001a],
bradykinin and acetylcholine [Minai et al 2001]. It has also been shown that ACE
inhibition but not angiotensin receptor blockade augments the release of t-PA from
the coronary circulation [Matsumoto et al 2003], These findings confirm our own in
the peripheral circulation but have not been studied in patients with atheromatous
coronary disease or heart failure.
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7.8 CLINICAL RELEVANCE
It has been previously demonstrated that there is a clear link between impaired
endothelial release of t-PA and risk factors for the progression of atherosclerosis. In
man, the capacity of the coronary circulation in vivo to release t-PA in response to
acute stimulation with substance P, is inversely associated with increasing
atheromatous plaque burden and smoking habit [Newby et al 1999b], Moreover, both
bradykinin and substance P mediated endothelial t-PA release are impaired in the
forearm circulation of cigarette smokers. [Newby et al 1999b; Pretorius et al 2002].
Given that the vasomotor effects of bradykinin in the human coronary circulation are
attenuated at sites of atheromatous plaque [Kuga et al 1995], it is likely that
bradykinin mediated endothelial t-PA release may also be impaired.
In the early studies of ACE inhibitor therapy in heart failure it was noted that the
reduction in mortality in the treatment arms of the studies was not only due to
reduction in pump-failure but also to a reduction thrombotic vascular events [The
CONSENSUS Trial Study Group 1987; SOLVD 1991], This reduction in thrombotic
vascular events occurs in all cardiovascular conditions treated by ACE inhibition.
The HOPE study [2000] showed that treatment of patients with a history of vascular
disease, with ramipril, reduced the incidence of cardiovascular death from 17.8% in
the placebo group to 14% in the group treated with ramipril. The more recent
EUROPA [2003] study showed that treatment with perindopril in patients with 'high
risk' vascular disease reduced the incidence of myocardial infarction from 6.2% in
patients treated with placebo to 4.8% (RR reduction 22%, CI 10-33%, p=0.001)
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[EUROPA 2003]. In addition, the recent OPTIMAAL study [2002] compared
treatment with the angiotensin receptor blocker losartan and the ACE inhibitor
captopril in patients after myocardial infarction. Treatment with captopril reduced the
incidence of recurrent myocardial infarction from 15.3% to 13.3% (RR reduction
13%, CI 1 -34%, p=0.03) when compared to losartan therapy. This evidence confirms
that ACE inhibition has benefits above and beyond reduction of angiotensin II that is
most likely to be due to the effects ofACE inhibition on bradykinin.
In this thesis it has been shown that bradykinin is an important mediator of vascular
protection and repair, due to its effects on endogenous fibrinolysis and vasomotor
tone. It has also been shown that these effects can be augmented by ACE inhibition.
Further work is required, as outlined above, to elucidate the role of other mediators
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